

AF



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07H 15/24	A1	(11) International Publication Number: WO 97/39007 (43) International Publication Date: 23 October 1997 (23.10.97)
(21) International Application Number: PCT/US97/05920 (22) International Filing Date: 10 April 1997 (10.04.97) (30) Priority Data: 08/635,243 12 April 1996 (12.04.96) US (71) Applicant: PRO-NEURON, INC. [US/US]; 1530 East Jefferson Street, Rockville, MD 20852 (US). (72) Inventors: KENTEN, John, H.; 21021 Sugar Ridge Terrace, Boyds, MD 20841 (US). SIMPSON, David, M.; 6611 Sulky Lane, N. Bethesda, MD 20852 (US). (74) Agent: BYRNE, Thomas, E.; Nixon & Vanderhye P.C., 8th floor, 1100 North Glebe Road, Arlington, VA 22201-4714 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: COMPOUNDS AND METHODS FOR THE SELECTIVE TREATMENT OF CANCER AND BACTERIAL INFECTIONS		
(57) Abstract <p>The present invention relates to compounds containing an anthracycline group such as doxorubicin, daunorubicin or a derivative thereof. The compounds of the invention also contain ester, glycoside or glucuronide structures which are hydrolyzed by the corresponding esterase, glycosidase or glucuronidase. These compounds possess potent cytotoxic activity which is developed after the hydrolysis of the ester or glycoside group of the compound and are effective in the inhibition of tumor cells and bacterial growth after activation.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

COMPOUNDS AND METHODS FOR THE SELECTIVE TREATMENT OF CANCER AND BACTERIAL INFECTIONS

FIELD OF THE INVENTION


5 The present invention relates to a new class of glucuronides, esters, and glycosides whose aglycone activity is more highly toxic than normally found for such compounds, as well as to methods of preparation of such glucuronides, esters, and glycosides. The present invention also relates to the treatment of
10 tumors with an ester, or glucuronide and/or glycoside and optionally an enzyme such as an esterase, glucuronidase and/or glycosidase. The enzyme at the site of the tumor is either (i) a property of the tumor or (ii) is delivered there (targeted), or a combination of the two. The targeting is accomplished via a binding species or an organism. The invention further relates to the treatment of
15 bacterial infections, in particular, infections having esterase, glucuronidase and/or glycosidase activity.

BACKGROUND OF THE INVENTION

20

The selectivity of anti-cancer drugs is poor and most of the drugs used for treatment have dose limiting toxicity (typically bone marrow toxicity but other tissues are affected depending on the anti-cancer drug). The use of doxorubicin, for example, is dose limited due to its cardiac toxicity and its
25 myelosuppressive effect. Numerous attempts have been made to isolate related anthracycline drugs which show improved properties but doxorubicin and daunorubicin remain two of the most useful drugs for treatment of cancers and leukemias (Young, RC et al, New England J Medicine 1981, 305, 139-153; Zunino F and Capranico G, Anti-Cancer Drugs Design 1990, 5, 307-317; EP 0
30 441 218 A2).

The most interesting drugs for use as prodrugs are those which are toxic at low levels with IC₅₀ (inhibitory concentration causing 50% inhibition of growth) <10⁻⁵ M. Examples of such agents include morpholinyl anthracyclines (Streeter DG et al, Cancer Chemother Pharmacol 1985, 14, 160-164; US 4,301,277), barminomycins (Uchida T, et al, The J of Antibiotics, 1988, XLI, 404-408) actinomycin D, and anthracycline analogs bearing latent alkylating substituents (US Patent 5,196,522). Morpholinyl anthracyclines such as compound 1 (see below) can dissociate in solution to form the reactive iminium compound 2; and compound 3, an anthracycline analog bearing a latent aldehyde, can undergo hydrolysis of the diacetoxyl group by esterases in vivo followed by cyclization to form the analogous iminium compound 4.



Reactive iminium ions are formed by the reaction of amines with carbonyl groups such as aldehydes and ketones.

The need for more toxic agents as prodrugs has been suggested by a number of workers in this area (Henle KJ, et al Radiation Res, 1988, 115, 373-

386). Attempts have also been made to improve the properties of the anthracycline cancer drugs by making glycoside modifications to generate activatable prodrugs (EP 0 441 218 A2, Leenders Ruben GG et al Tet Lett. 1995, 36, 1701-1704, EP 0 565 133 A2, WO 92/19639). These anthracycline
5 glycosides do not make use of the more potent anthracyclines resulting in less desirable anthracycline prodrugs due to the clinical problems of large doses and increased cost of synthesis.

Antibodies which are specific for tumors are well known in the art.
10 Tumor specific antibodies have been used to target toxins in attempts to develop cancer therapies.

The production of drug antibody conjugates has been achieved with some success *in vitro* but with disappointing results in tumor bearing mice and
15 clinical studies (Garnett MC, et al Int J Cancer 1983, 31 661-670, Embleton MJ et al Br J Cancer 1983, 47 43-49).

Attempts have been made to improve selective delivery of cytotoxic agents to tumors using antibodies coupled to enzymes. Conjugation of enzymes
20 such as ricin and other ribosome inactivating proteins to antibodies has been used to target enzymes to tumors. In these studies, the enzyme is also the active toxin entering the cell and catalytically inactivating it by modification of the ribosomes (Moller G, Immunol Rev 1982;62).

25 In other studies, attempts have been made to use the activities of enzymes conjugated to targeting antibodies to generate cytotoxic agents for targeted tumor killing. The early work on this principle used glucose oxidase as the enzyme (Philpott GD, et al J Immunology 1973, 111, 921-929). See also Parker et al, 1975 Proc Nat Acad Sci USA 72, 338-342.

WO 87/03205 discloses enzyme-coupled antibody, in which the enzyme is characterized by its ability to catalyze reactions which result in the death of cells bearing antigenic sites which the antibody can bind. See also US Patent 4975278. In animal studies, tumor regressions were seen with the targeting of
5 the CC 49 anti tag 72 antibody as a conjugate to beta-lactamase to tumors followed by the treatment of the animals with a vinblastine prodrug substrate for beta-lactamase, Meyer et al (Cancer Res 1993 53, 3956-3963). In these studies, in addition to the antibody-enzyme conjugates, the drug antibody conjugates were evaluated and shown to be relatively ineffective and required
10 very large doses of antibody when compared to enzyme activation

Targeting of glycosidic enzymes has also been successfully used. In one example, a tumor specific antibody was chemically cross linked to the enzyme *E.coli* beta-glucuronidase and used to target a rat hepatoma cell line. This
15 targeted beta-glucuronidase was used to activate p-di-2-chloroethylaminophenyl-beta-D-glucuronide prodrug to its active drug N,N-di-(2-chloroethyl) 4-hydroxyaniline (Wang SM et al Cancer Res 1992 Aug 15;52(16):4484-91)

20 In a further demonstration of this approach, a pan carcinoma antibody was chemically linked to *E.coli* beta-glucuronidase generating a conjugate which was able to specifically target various carcinoma cells. The prodrug used in this study was a glucuronide of epirubicin which resulted in a detoxification of the parent drug up to 1000 fold. This glucuronide was isolated from the urine
25 of patients treated with epirubicin. The *in vitro* data demonstrated good levels of activation and cytotoxicity using these conjugates (Haisma HJ et al Br J Cancer 1992 Sep;66(3):474-8).

In another study making use of (i) a conjugate of *E.coli* beta
30 galactosidase to an anti-CEA antibody Col1 and (ii) a galactoside of 5-

fluorouridine, targeted activation was also demonstrated (Abraham R et al 1994 Cell Biophysics 24/25, 127-133).

Prodrug approaches have also been used clinically making use of the
5 prokaryotic enzyme carboxypeptidase-G2 fused to anti CEA antibodies
(Bagshawe KD et al Br J Cancer 1988 58:700-703). In a study aimed at
producing a less immunogenic antibody fusion, which may have advantages
over mouse antibodies and bacterial enzymes, a fusion with the human beta
glucuronidase was made to a humanized anti CEA antibody. This was achieved
10 by making a genetic construction allowing reproducible production of the
therapeutic antibody (Bosslet K et al Br J Cancer 1992 65:234-238, EP 0501215
A2). This humanized anti CEA antibody human beta glucuronidase fusion
protein has been demonstrated to activate a glucuronide of doxorubicin (see WO
92/19639) in tumor bearing mice to achieve some reduction in tumor growth
15 and 10 fold higher levels of doxorubicin in the tumor (Bosslet K et al, 1994
Cancer Res. 54, 2151-2159). In an approach similar to that described by Bosslet
et al., the use of human antibodies and human lysozyme has also been proposed
to reduce the potential problems associated with immunogenic antibodies and
enzymes (WO 90/07929).

20

The potential for the use of exogenous glycosidic enzymes in a non
targeted format has been investigated (Tshiersch B, Schwabe K, Sydow G, and
Graffi A Cancer Treat Rep 1977 61:1489-1493). In this study a combination of
alpha-L-arabinofuranosidase from *Aspergillus niger* was used in combination
25 with a prodrug form of beta-peltatin A, beta-peltatin A-alpha-L-
arabinofuranoside. The aim of this approach was to make use of the lower pH
optimum for the alpha-L-arabinofuranosidase to develop selective activation in
tumors based on the lower pH found in tumors. This group also made use of the
ability to affect the tumor pH by glucose infusion.

30

The potential for the use of endogenous glycosidic enzymes in a non targeted format has been investigated. US Patents 4,327,074, 4,337,760; 4,481,195; 4,584,368; and 5,005,588 describe the potential of using beta-glucuronidase activity present in tumors. The inventors note that the effect can
5 be enhanced by the use of glucose and alkalinization to increase the differences in pH between the tumor and the normal tissues. The use of glucose allows the tumor pH to be lowered significantly and the use of a base such as sodium bicarbonate allows the urine pH and other areas of normal tissue to remain at pH in the range of 7.4. The lowering of the tumor pH can be as much as 0.5 pH
10 unit in some cases (Cancer Res 49, 4373-4384, 1989). US Patent 4,248,999 discloses the use of 5-fluorouracil as a glucuronide (and other glycosides) by linking it to the C6 position of the uracil ring. Protocols for the improvement of therapy with glucuronide prodrugs have also been suggested which make use of the potential for endogenous glucuronidase activity, increasing the whole body
15 pH and lowering the tumor pH


The potential of using virus and/or nucleic acid targeted prodrug activation has also been investigated. In an example of this approach, the enzyme cytosine deaminase has been targeted using a retroviral vector to
20 achieve the selective delivery and activation of the prodrug 5-fluorocytosine. This has been demonstrated with the generation of retroviral vectors which have incorporated the cytosine deaminase gene from yeast under control of the CEA promoter (Huber BE et al. 1993, Cancer Res 53, 4619-4626). In a similar approach the herpes simplex virus thymidine kinase (HSV-tk) has been
25 incorporated into retroviral vectors to activate ganciclovir to its toxic phosphorylated form (J. Michael DiMaio et al 1994, Surgery 116, 205-213). Other viruses may be used in this targeting approach such as adenovirus, fowlpox, newcastles disease. These viruses are being explored in the treatment of cancer. The delivery of the virus may be direct through the use of an
30 infectious particle which optionally has been engineered to have a selective

tissue tropism (i.e., by inclusion of antibody binding domains (Chu et al, J Virol 1995, 69 2659-63)). In an alternative method the virus is targeted by the use of other vehicles such as liposomes in either a targeted (by binding moieties, i.e., antibodies) or untargeted fashion (Bichko V et al 1994, J Virology 68, 5247-5252). The targeting and delivery of genes to activate prodrugs can also occur via the delivery of DNA (not in the form of a virus). An encapsulation method can be used for delivery either via liposomes or through the use of viral like particles to package the DNA as has been demonstrated with a number of E. coli viruses.

144

SUMMARY OF THE INVENTION

The present invention relates to compounds containing an anthracycline group such as doxorubicin, daunorubicin or a derivative thereof. The compounds of the invention also contain ester, glycoside or glucuronide structures which are hydrolyzed by the corresponding esterase, glycosidase or glucuronidase. These compounds possess potent cytotoxic activity which is developed after the hydrolysis of the ester or glycoside group of the compound and are effective in the inhibition of tumor cells and bacterial growth, after activation. Included are compounds having the formula:



25

where:

R¹ is a radical of an anthracyclinone where the point of attachment is the 3' nitrogen of the daunosamine sugar;

R^2 is H, alkyl having from 1 to 6 carbon atoms, phenyl or aromatic or heteroaromatic having from 1 to 10 carbon atoms substituted with NO_2 , CN, F, Cl, OH, OMe, or alkoxy having from 1 to 6 carbon atoms, COMe, CF_3 , COOH, COO(alkyl or aryl) having from 1 to 10 carbon atoms;


5 R^3 is cyano, methoxy, ethoxy, alkoxy having from 3 to 18 carbon atoms, phenoxy or aryloxy having from 1-10 carbon atoms substituted with NO_2 , CN, F, Cl, OH, alkoxy having from 1 to 6 carbon atoms, COMe, CF_3 , COOH, or COO (alkyl or aryl) having from 1 to 10 carbon atoms, acetoxy, propionyloxy, trimethylacetoxy, or benzyloxy;

10 $X = \text{CH}_2$, O, S, or N substituted by H, alkyl or acyl having from 1 to 6 carbon atoms, phenyl, or aromatic or heteroaromatic having from 1 to 10 carbon atoms substituted with methyl, ethyl, acetyl or benzoyl;

$n = 2$ if $X = \text{O}$, S, or substituted N;

$n = 1$ or 2 if $X = \text{CH}_2$;

15 B is O, NHCOO, or one of the following substituted aromatics:



20

where M is H, NO_2 , CN, F, Cl, OH, alkoxy having from 1 to 18 carbon atoms, COMe, CF_3 , COOH, COO(alkyl or aryl) having from 1 to 10 carbon atoms,

phenyl, aromatic or heteroaromatic having from 1 to 10 carbon atoms, methyl or alkyl having from 2 to 18 carbon atoms; and

Z is a glycosyl, or substituted aliphatic or aromatic acyl having from 1 to 18 carbon atoms attached to the aromatic or carbamoyl O of B at the anomeric
5 carbon of Z;

provided that where R^3 is aryloxy or acyloxy, BZ cannot be the same as R^3 .

BRIEF DESCRIPTION OF THE DRAWINGS

10

Figure 1 illustrates the mechanisms by which two compounds of claim 1 can break down to form an amino aldehyde, which spontaneously forms the reactive iminium ion.

15

Figure 2 illustrates the breakdown of an inactivated amino prodrug incorporating a self-immolative linker.

Figure 3 illustrates another version of a self-immolative linker.

20

Figure 4 illustrates breakdown of the prodrug to form an unsaturated ketone.

Figure 5 schematically illustrates the potential mechanism of action of one example of the anthracyclines class of prodrugs. This prodrug is structured to be activated by the enzyme glucuronidase.

5 Figure 6 is a schematic illustration of a synthetic route to a glucuronide of doxorubicin and daunorubicin (Example 2)

Figure 7 is a schematic illustration of a synthetic route to a glucuronide of doxorubicin (Example 3).

10

The invention, as well as other objects, features and advantages thereof, will be understood more clearly and fully from the following detailed description when read with reference to the accompanying Figures.

15

DETAILED DESCRIPTION OF THE INVENTION

The subject invention relates to a novel family of prodrugs for the treatment of cancer and bacterial infections which are based on the site specific activation of the prodrugs by various methods involving enzymes. Upon
20 activation, the prodrugs are capable of undergoing spontaneous reactions leading to the formation of reactive iminium ions. In particular, the compounds of the present invention are activatable by glycosidases including glucuronidases, and esterases.

Advantageous anticancer drugs which can be modified according to the subject invention include anthracyclines such as doxorubicin, deoxydoxorubicin and daunorubicin, epirubicin and idarubicin, or derivatives thereof.

5

The compounds of the invention are activated by enzymatic removal of glycoside structure to yield active intermediates, see Figure 5. An example of activation using a glucuronide and glucuronidase is shown in Figure 5.

10 The compounds of the invention are effective in the inhibition of human tumor growth and bacterial growth. The compounds may be divided into three classes based on the strategy of inactivation by glycosylation or esterification.

1. Glycosylation and esterification serves to mask a latent aldehyde or
15 ketone from reaction with the amino group of the anthracycline. Figure 1 illustrates the mechanisms by which two compounds of claim 1 can break down to form an amino aldehyde, which spontaneously forms the reactive iminium ion. The sugar can be directly attached to the latent aldehyde, or can be connected indirectly through a self-immolative linker. Figure 3 illustrates
20 another version of a self-immolative linker

2. Glycosylation and esterification serves to mask the reactivity of the amino group of the anthracycline. The reactivity of the aldehyde or ketone is

temporarily reduced as well, in order to inhibit undesirable intermolecular reactions with proteins, for example. Figure 2 illustrates the breakdown of an inactivated amino prodrug incorporating a self-immolative linker. After the latent aldehyde is unmasked (hydrolysis at the acidic tumor pH), the amino
5 aldehyde spontaneously forms the reactive iminium ion.

3 Glycosylation and esterification serves to mask a latent aldehyde or ketone which is reactive with the amino group of the anthracycline at the a or b position (as well as at the carbonyl) in a manner designed to give a reactive
10 iminium ion. Figure 4 illustrates breakdown of the prodrug to form an unsaturated ketone. Michael addition gives the a-halo amine, which dehalogenates spontaneously to form a reactive iminium ion.

I. Definitions

15

Organism means any bacteria, virus, parasite, or other living thing with a size less than 100 μ M in any dimension.

Binding species means any molecule which has an affinity or avidity for
20 another molecule greater than 1mM. Examples of such molecules are usually defined as pairs where one binds to another of different or the same structure. Examples are: avidin/biotin; antibody/antigen; receptor/ligand; metal ion/ligand; protein/protein; lectin/carbohydrate; and nucleic acid/protein.

Humanized antibody means an antibody which has been modified to incorporate human sequences into it resulting in an antibody which is more like a human antibody. The term also includes antibodies which have been mutated to reduce immunogenicity.

5

Glycosyl group is a single molecular moiety added to another molecule. Examples of glycosyl groups which can be added to the molecules of the invention are galactosyl, glucuronyl, deoxy-glucosyl, iduronyl, glucosyl, N-acetyl glucosaminosyl, fructosyl, sialosyl, hyaluronosyl, sedoheptulosyl, xylulosyl, ribulosyl, ribosyl, xylitosyl, daunosaminosyl, arabinosyl, fucosyl, deoxy-ribosyl, mannosyl, N-acetyl-galactosyl, rhamnosyl, 3,6-anhydro-galactosyl, sialylfucosyl, and xylosyl. Molecules containing these glycosyl moieties are called glycosides. Molecules containing these glycosyl moieties, the glycosides, are substrates for the respective glycosidase

15

Anthracyclines are molecular moieties characterized by the presence of four fused six-membered rings forming a substituted tetrahydronaphthacene quinone (aglycone) moiety conjugated via glycosidic linkages to a side chain containing one or more glycosyl groups. Most clinically important anthracyclines contain an amino glycosyl attached to the aglycone portion. The number and or distribution of hydroxyls or methoxyls in the aglycone vary and semisynthetic anthracyclines can contain functional groups not found in the natural products. Examples of compounds which form the anthracyclines of

20

the present invention are: adriamycin, daunomycin, carminomycin, rubidazole, carminomycin, zorubicin, epirubicin, idarubicin, deoxydoxorubicin, 4'-demethoxydaunorubicin, ditrisarubicins, betaclamycins, 2-hydroxyaclacinomycins, 4'-O-tetrahydropyranyladriamycin, barminomycins, 5 baumycins, annamycin, pirarubicin, THP-doxorubicin, pirarubicin, aclarubicin, zorubicin, iododoxorubicin, AD-32, detorubicin, esorubicin, marcellomycin, quelamycin, rodorubicin, menogaril and nogalomycin. Examples are also presented in US 4,411,834, hereby incorporated by reference

10 *Heteroaromatics* are ring structures having from 5 to 8 atoms in the ring which contain in addition to carbon atoms, other atom types in the ring. These other atoms "hetero-atoms" can be S, O, N, P, Si. In addition to these hetero-atoms, the ring structure can also contain at least two double bonds as part of the ring structure. The number of heteroatoms in a ring can be from 1 to 4. Also, 15 multiple rings can be fused to form a heteroaromatic as in the case of adenine. Examples of such heteroaromatics are furan, pyridine, indole, guanine, adenine, thiophene. These heteroaromatics can be derivatized with NO₂, CN, F, Cl, OH, alkoxy having from 1 to 6 carbon atoms, COMe, CF₃, COOH, or COO (alkyl or aryl) having from 1 to 10 carbon atoms, acetoxo, propionyloxy, 20 trimethylacetoxo, or benzoyloxy, attached to the ring structure.

Glycosidase means a molecular species which is able to effect the removal of a glycoside or glucuronide from a molecular species containing a

glycoside or glucuronide. Examples of glycosidases are glucuronidase, galactosidase, glucosidase, iduronidase, lysozyme, amylase, N-acetyl glucosaminidase, fructosidase, sialidase, hyaluronidase, etc.; these being defined by the activity which each possess. Glycosidase activity is not a property solely
5 of proteins. Synthetic chemistry can also generate similar activities (ability to hydrolyse the glycosidic bond). Examples of substrates for such glycosidases are lactose, glycogen, starch, cellulose, sucrose, nitrophenyl-maltohexoside, maltotriose, bromo-chloro-indolyl galactoside, methylumbelliferyl-N-acetylneuraminic acid, nitrophenyl glucoside.

10

A latent aldehyde or ketone is a functional group that can undergo conversion to form an aldehyde or ketone. For example, diacetoxy acetals such as $\text{CH}(\text{OCOCMe}_3)_2$ can undergo hydrolysis of the ester groups to form $\text{CH}=\text{O}$; the group $\text{C}=\text{NNHCOCH}_2\text{CH}_2\text{SS}(2\text{-pyridyl})$ is very stable at pH 7.4, but has a
15 half life of 1.8 hours at pH 5.0 and hydrolyzes to form $\text{C}=\text{O}$ (*Bioconjugate Chem.*, Vol. 2, 133-141, 1991); and the hydrolysis of silyl enol ethers such as $\text{CH}=\text{CHOSiR}_3$ to form $\text{CH}_2\text{CH}=\text{O}$ is well preceded in the literature.

II. Synthesis of the Compounds of the Invention

A. Synthesis of Glucuronyl Prodrugs of Anthracycline Drugs.

In general, synthesis is as follows: acetyl protected bromoglucuronic
5 acid methyl esters are converted to the beta-benzyl glucuronates. At low
temperature, the benzyl groups are cleaved to give the beta-alcohol anomer,
which is quickly silylated to give the beta-trimethylsilyl glucuronide.
Alternatively, acetyl protected glucuronic acid esters with a free hydroxyl at the
anomeric position are reacted with trimethylsilyldialkylamines to give the β -
10 trimethylsilyl glucuronide with high selectivity. The silyl glycoside is reacted at
low temperature with an alkenyl acetal to give the glucuronyl mixed acetal.
Ozonolysis of the alkene produces an aldehyde, which is used for the reductive
alkylation of the anthracyclines. The ester protecting groups are removed by
saponification to give the prodrugs.

15

B. Synthesis of Diacyloxy Prodrugs of Anthracycline Drugs.

In general, synthesis is as follows: alkenyl alcohols are oxidized to
the aldehydes using an oxidant such as catalytic tetra-n-propylammonium
perruthenate and N-methylmorpholine-N-oxide. The alkenyl aldehydes are
20 reacted with carboxylic acid anhydrides using a Lewis acid activator such as
boron trifluoride etherate to give the diacyloxy alkenes. Ozonolysis of the
alkenes produces diacyloxy aldehydes, which are used for the reductive
alkylation of the anthracyclines.

III. Treatment of Cancer

Treatment of cancer in parients, i.e., mammals including humans, is
5 achieved by administering the compounds and compositions of the invention.
Examples of cancers which are treatable according to the invention are lung,
colon, breast, pancreatic, ovarian, melanoma, and stomach cancers. Solid
tumors offer the best opportunity for the use of the compounds of the present
invention. These allow the generation of necrotic regions more readily able to
10 activate the esters, glucuronides or glycosides of the present invention.

A. Activation of Prodrug by Endogenous Enzymes

In one embodiment of the invention, activation of the prodrug
15 occurs due to endogenous enzyme in the tumor such as glucuronidase. Tumor
pH is modulated using glucose and bicarbonate infusions which lower the tumor
pH allowing the endogenous lysosomal enzymes to be more active than in
normal tissue. The prodrug is then injected at doses from 1 miligram to 50
grams and at dosing intervals based on the response to the therapy and levels of
20 prodrug products in the serum. The prodrug dose is advantageously in the range
of 50 μg -5000 mg/m^2 with dose cycles of tumor pH modulation and prodrug
administration each day for up to 20 days, depending on the level of non-
specific activation as measured by the appearance of prodrug products in the
serum. During the course of treatment patients are monitored for adverse
25 cardiac toxicity, myelosuppression, liver and kidney function. This cycle of
therapy is repeated a number of times (3-10 times) as required.

B. Glucuronide Therapy

In order to prepare the patient for glucuronide therapy, the tumor pH is lowered to improve the therapeutic effect of the glucuronidase activation. The patient is typically first given juices and asked to empty his bladder. This is followed by a dose of 100 g of glucose. After 30 min to 2 hrs, the patient then receives a drip which delivers 10% glucose and 60 milliequivalents of sodium bicarbonate. This drip delivers up to 1 liter over one hour. At 30 min into the drip, the patient empties his bladder to determine the effectiveness of the therapy in causing alkalanization of the urine. Alkalanization is also achieved by the use of inhibitors of carbonic anhydrase (i.e., acetazolamide) in combination with bicarbonate to achieve a more prolonged affect.

The treatment with the glucuronide drug is initiated when it has been determined that the glucose and bicarbonate drip has achieved alkanization of the urine. The analysis of the 30 min urine sample should show a pH above 7.4. The glucuronide prodrug is typically given as an infusion in order to maintain a sustained level of drug in the blood for a period of one hour or more. Alternatively, the prodrug is given as a bolus IV. The dose of the prodrug is a maximum of 500 mg/m² per treatment round but can be fractionated into multiple doses. Patients may be eligible for further treatment based on the indications of toxic side effects. Treatment rounds occur at intervals of 3-6 weeks.

Patients are monitored for adequate organ function including hematological function (white cell count, platelet count), hepatic function (bilirubin, aspartate amino transferase, alanine aminotransferase), renal functions (creatinine levels) and pulmonary function (carbon monoxide diffusing capacity). This data is useful as a basis for controlling dose and intervals during treatment.

In one embodiment of the invention activation at a desired target is accomplished by causing the target to synthesize the activating species. For example, it is possible to direct tumor cells to synthesize enzymes which are able to activate prodrugs. For example, a retroviral vector which contains a glycosidic enzyme activity is generated which is capable of activating a compound of the invention. This viral vector is then targeted via the selective nature of the infectious agent for dividing cells or via the selective expression systems within the cell. Other viruses can be used in this targeting approach such as adenovirus, fowlpox, newcastles disease. The delivery of the virus can be direct through the use of an infectious particle which optionally has been engineered to have a selective tissue tropism (i.e., by inclusion of antibody binding domains (cf Winters)). In an alternative method, the virus is targeted by the use of other vehicles such as liposomes in either a targeted (by binding moieties, i.e., antibodies) or untargeted fashion (Bichko V et al 1994, J Virology 68, 5247-5252).

The targeting and delivery of genes to activate prodrugs can also occur via the delivery of DNA (not in the form of a virus). An encapsulation method is used for delivery either via liposomes or through the use of viral like particles to package the DNA, as has been demonstrated with a number of E. coli viruses. Thus, this type of system can be used to target the prodrug activation of the compounds of the invention. Targeting the expression is accomplished either via the targeting or the selective expression of glucuronidases or other glycosidases which then activate the prodrugs of the invention. This viral targeting of the activating agent gene to achieve the selective activation of the prodrugs of the invention can also be achieved using other organisms which show tropisms for tissues and organs. In an advantageous embodiment, the glucuronidase and/or glycosidase are expressed in these virally or organism based targeted systems in a form which does not diffuse away from the tumor or other target site, by making use of, for example, transmembrane domains of

membrane binding proteins, the binding domains of antibodies, etc. known in the art.

Also the use of transformed cells may be used to target the delivery of enzyme activity to the site of therapy. See Cancer Immunol Immunother. 1994 May; 38(5): 299-303, Cancer, 1994, Mar. 15, 73(6)1731-7.

C. Activation of Prodrug by Exogeneous Enzymes

In another embodiment, activation of the prodrug is accomplished by the administration of a dose of enzyme. Examples of glycosidase enzymes which are useful in the subject invention are glucuronidase, lysozyme, beta-galactosidase, alpha-galactosidase, beta-glucosidase, or other lysosomal enzymes which are able to hydrolyze glycosides. Ideally these enzymes should have a low pH optimum, i.e., below pH6. For example, from 1-100 mg of glucuronidase is administered followed by a clearance period during which the level of glucuronidase in the serum is monitored. At a time point after the injection of the enzyme, the level of enzyme reaches a level where the potential for activation of the prodrug is not significant. This time point will typically be from 12 hrs to 90 hrs after injection of the enzyme. At this time, when the level of enzyme has reached a level in serum not to cause over activation of the prodrug, the prodrug is injected at doses from 100 μ g to 50 grams and at dosing intervals based on the patients response to the therapy, and/or levels of prodrug products in the serum. Advantageously, the prodrug dose is in the range of 50 μ g-5000 mg/m² of prodrug with doses each day for up to 20 days depending on the level of non-specific activation (measured by the appearance of prodrug products in the serum).

Optionally, tumor pH is modulated using glucose and bicarbonate as described in the section above on activation by endogenous enzymes. This

allows the tumor pH to be lowered permitting the accumulated glucuronidase to be more active than in normal tissues.

Adverse cardiac toxicity, myelosuppression, liver and kidney function
5 are monitored during treatment. This cycle of therapy is repeated a number of times (3-10 times) as required.

D. Activation of Prodrug by an Antibody-Enzyme Fusion

In the case of targeted glucuronidase and glycosidases, examples of
10 targeting antibodies which can be used are OncoScint® (Cytogen Corp
Princeton NJ) which is capable of achieving in some cases tumor:normal tissue
ratios of greater than 20:1 (Stern H, et al Cancer Investigation 1993, 11(2) 129-
134), CA125, BR96, B72.3, CC49, Col 1, 17-1A, and 16.88, which include both
mouse, humanized and human antibodies (Siddiki B et al Int J Cancer 1993 54,
15 467-474; Weiner LM et al J Immunotherapy 13, 110-116; Muraro R. et al
Cancer Res 1985 45, 5769-5780; Colcher D et al Cancer Res 1988 48, 4597-
4603; Jager RD, et al Seminars in Nuclear Medicine 1993, XXIII, 165-179). See
also U.S. Patent application Ser. Nos. 07/773,042 and 07/919,851 each of which
is hereby incorporated in its entirety by reference. These antibodies are linked
20 by a chemical linkage or via the construction of genetic fusions. These
molecules are dosed prior to the administration of compounds of the invention.

An antibody-enzyme fusion is administered at up to 1 gm in various
dosing schedules, but typically in the range 1-200 mg per dose as a single dose
25 which may be infused over a period of time from 10 min to 24 hr. The dose of
antibody-enzyme can also be given in multiple dose injections. After antibody-
enzyme infusion periodically the levels of enzyme are measured and the
antibody titers. The typical time allowed for this clearance is from 1 to 14 days
When the levels of prodrug activating enzyme have reached a level at which
30 little toxic activation can occur, the prodrug is administered. The prodrug is

injected at doses up to 5 grams and at dosing intervals based on the response to therapy and levels of prodrug products in the serum. Advantageously, the prodrug dose is in the range of 50 μ g-5000 mg/m of prodrug with doses each day for up to 20 days. The rate of administration will vary depending on the
5 level of non-specific activation as measured by the appearance of prodrug products in the serum and monitoring of the dose limiting toxicity using HPLC analysis of extracted blood samples and serum chemistry analysis.

In addition, tumor pH modulation using glucose and bicarbonate to
10 lower the pH within the tumor is optionally used in this embodiment. This increases the activity of the prodrug activating enzymes if these had pH optima which were lower than the normal leading to the delivery of more drug to the tumor.

15 During the course of treatment patients are monitored for adverse cardiac toxicity and myelosuppression. The cycle of therapy is repeated a number of times.

This targeting of the prodrug activating glycosidase activity is achieved
20 using a number of binding species which have been shown to have selectivity for the tumors or tissues where selective activation is desired. Examples of targeting agents are growth factors, lectins, amino acids, vitamins for which there are receptors and/or transporters able to act as binding species for targeting. These targeting agents are linked to the glycosidase activity to allow
25 selective accumulation of the activating enzyme mediated via these binding species.

IV. Use of Glycoside Prodrugs as Antibiotics

The glycoside prodrugs of the invention are useful in the treatment of bacterial infections where the bacteria involved have a specific glycosidase activity. Examples of such bacteria are streptococci, staphylococci, and *E. coli*. Treatment is similar to that described above for cancer but there is no need for hyperacidification. The alkalization of the urine is carried out to reduce the non-specific activation in the bladder as described above. Bicarbonate drips or drug treatments (e.g., acetazolamide) can be used. Having established this alkalization, the prodrug is given via the bicarbonate drip or by intravenous injection in a suitable vehicle. Alkalinization can also be achieved by oral bicarbonate.

In one embodiment of the invention, the prodrugs are used without alkalization due to the stability of the glycoside pro- group to the conditions present in the bladder.

V. Formulation and Administration

The present invention also encompasses pharmaceutical compositions, combinations and methods for treating cancers and other tumors. More particularly, the invention includes combinations comprising immunoconjugates (targeting protein and catalytic protein, or targeting antibody and catalytic antibody (bispecific antibodies)) and the corresponding prodrug or prodrugs for use in a method for treating tumors wherein a mammalian host is treated in a pharmaceutically acceptable manner with a pharmaceutically effective amount of a targeting protein catalytic protein conjugate or conjugates or bispecific antibody or antibodies and a pharmaceutically effective amount of a prodrug or prodrugs. In addition the invention includes combinations comprising immunoconjugates (targeting protein and catalytic protein, or targeting antibody

and catalytic antibody (bispecific antibodies)) and the corresponding prodrug or prodrugs for use in a method for treating tumors wherein a mammalian host is treated in a pharmaceutically acceptable manner with a pharmaceutically effective amount of a targeting protein catalytic protein conjugate or conjugates
5 or bispecific antibody or antibodies and a pharmaceutically effective amount of a prodrug or prodrugs. The combination and methods of this invention are useful in treating humans and animals

The prodrugs and/or the binding species or organism is administered by
10 any suitable route, preferably parenterally, e.g., by injection or infusion. These compounds are administered using conventional modes of administration including, but not limited to, intravenous, intraperitoneal, oral, intralymphatic, or administration directly into the tumor. Intravenous administration is particularly advantageous.

15

The compositions of the invention--comprising the binding species or organism or prodrugs--can be in a variety of dosage forms which include, but are not limited to, liquid solutions or suspensions, tablets, pills, powders, suppositories, polymeric microcapsules or microvesicles, liposomes, and
20 injectable or infusible solutions. The preferred form depends upon the mode of administration and the therapeutic application. For example, oral administration of the antibody-enzyme conjugate or bispecific antibody may be disfavored because the conjugate proteins tend to be degraded in the stomach if taken orally, e.g., in tablet form

25

Suitable formulations of the binding species or organisms or prodrug for parenteral administration include suspensions, solutions or emulsions of each component in oily or aqueous vehicles and optionally contain formulatory agents such as suspending, establishing and/or dispersing agents. Alternatively,
30 the binding species or organism or prodrug is in powder form for reconstituting

with a suitable vehicle, e.g., sterile pyrogen-free water before use. If desired, the immunoconjugate antibody and/or prodrug is presented in unit dosage form. Formulations are conveniently prepared in isotonic saline for injection.

5 The most effective mode of administration and dosage regimen for the compositions of this invention depends upon the severity and course of the disease, the patient's health and response to treatment and the judgement of the treating physician. Accordingly, the dosages of the binding species, organisms and prodrugs should be titrated to the individual patient.

10

Nevertheless, an effective dose of the binding species or organisms of this invention is in the range of from about 1.0 to about 100 mg/m². An effective dose of the prodrug of the invention will range from 100 µg - 100 g/m². the precise doses at which the immunoconjugate and prodrug will be
15 administered will depend on the route of administration, body weight, and pathology of the patient, the nature of the prodrug, and the catalytic properties of the immunoconjugate. Since the prodrug is less cytotoxic than the parent drug, dosages in excess of those recognized in the art for the parent drug may be used.

20

EXAMPLES

25 **Example 1: Synthesis of Methyl 2,3,4-Tri-O-acetyl-1-O-trimethylsilyl-β-D-glucuronate 3.**

The compounds referred to in this synthesis are shown in Figure 7. The numbered intermediates of the Figure are cross-referenced in the text below in bold.

30

Methyl 2,3,4-tri-O-acetyl-1-O-trimethylsilyl- β -D-glucuronate 3 can be prepared following a published three-reaction procedure (see compounds 1-4 in Figure 2; L. F. Tietze, et al., *Carbohydrate Res.*, Vol. 148 (1986), 349-352); however, this procedure is technically demanding because it requires careful control of temperature. A simpler and more direct synthesis (compounds 1-3 in Figure 7) has been developed: the commercially available tetraacetate 1 was converted to a mixture of the α and β pyranoses 2 using a mixture of hydrazine and acetic acid in DMF. The anomeric mixture was treated with N-trimethylsilyldiethylamine in acetone at room temperature to give the desired β -silyl glucuronide 3 highly selectively (β : α > 98:2 by NMR).

The stereoselectivity of this reaction can be attributed to three factors. 1 Under the reaction conditions, the α and β pyranoses undergo facile anomerization. 2 Despite the fact that the α anomer is favored thermodynamically, the β -alkoxy anion is more reactive kinetically (Schmidt, et al., *Tetrahedron Lett.*, Vol. 25 (1984), 821; *Liebigs Ann. Chem.*, (1984), 1343) 3 Unfavorable 1,3-diaxial interactions with the glucuronyl H3 and H5 disfavor reaction between the bulky silylating reagent and the α alkoxide.

In detail, the synthesis is as follows:

Methyl 2,3,4-tri-O-acetyl-D-glucuronate 2

Methyl 1,2,3,4-tetra-O-acetyl-D-glucuronate 1 (2.50 g, 6.7 mmol) was added in one portion to a solution of hydrazine hydrate (380 mL, 8.0 mmol) and acetic acid (460 mL, 8.0 mmol) in 20 mL of DMF at room temperature. After 1 h, the mixture was partitioned between ethyl acetate (3 x 100 mL) and water (100 mL), 5% KHCO_3 (100 mL), and 0.1 M HCl (100 mL), and the organic phases were washed with brine (50 mL), dried over anhydrous MgSO_4 and concentrated in vacuo. The residue was purified by flash chromatography (40.

50, and 60% ethyl acetate/hexane) to give 0.21 g of recovered starting material (8%) and 1.66 g of the product as a colorless foam (74%), a 3.6:1 mixture of α and β anomers by NMR. Crystallization from ether/hexane gave the pure α anomer. R_f 0.26 (50% ethyl acetate/hexane); mp 104.5-109.5 °C; ^1H NMR (CDCl₃) δ 2.01 (s, 3), 2.02 (s, 3), 2.06 (s, 3), 3.72 (s, 3), 4.56 (d, 1, $J=10.1$, H5), 4.87 (dd, 1, $J=3.6, 10.2$, H2), 5.11-5.18 (m, 1, H4), 5.51 (d, 1, $J=3.6$, H1), 5.52-5.58 (m, 1, H3); ^{13}C NMR (CDCl₃) δ 20.47, 20.60, 52.88, 67.89, 69.06, 69.45, 70.70, 90.14, 168.50, 169.68, 170.04, 170.17.

10 *Methyl 2,3,4-tri-O-acetyl-1-O-trimethylsilyl- β -D-glucuronate 3*

Four mL of N-trimethylsilyldiethylamine was added to a solution of glucuronate **2** (700 mg, 2.0 mmol) in 4 mL of acetone. After 40 h at room temperature, the volatile components were evaporated in vacuo. The resultant brown solid, greater than 98% the b-silyl glucuronide **3** by NMR, was sufficiently pure to be used without further purification. The residue can be crystallized from ether and hexane. ^1H NMR (CDCl₃) δ 0.15 (s, 9), 2.01 (s, 6), 2.03 (s, 3), 3.74 (s, 3), 4.00-4.07 (m, 1, H5), 4.79 (d, 1, $J=7.4$, H1), 4.90-4.95 (m, 1), 5.18-5.26 (m, 2); ^{13}C NMR (CDCl₃) δ -0.06, 20.47, 20.60, 52.76, 69.44, 72.06, 72.66, 73.11, 95.56, 167.15, 169.17, 169.30, 170.14.

Example 2: Synthesis of Glucuronide Prodrugs of the Invention.

The compounds referred to in this synthesis are shown in Figure 6. The numbered intermediates of the Figure are cross-referenced in the text below in bold.

Compounds **9b** and **10b** are glucuronide prodrugs of doxorubicin and daunorubicin, respectively. Compound **9b** will undergo esterase hydrolysis of the methyl ester in vivo before glucuronidase catalyzed removal of the

glucuronic acid to give the drug. Compound 10b will undergo glucuronidase catalyzed removal of the glucuronic acid to give the drug without prior transformation.

5 Compounds 9b and 10b were made starting from methyl 2,3,4-tri-O-acetyl-1-O-trimethylsilyl- β -D-glucuronate 4 (see Example 1 for its preparation). Compound 4 was reacted with the readily available compound 5 using a Lewis acid catalyst at low temperature following the method described by Tietze, et al (*Carbohydrate Res.*, Vol. 180 (1988), 253-262). Working carefully, the β -
10 glucuronide 6 can be obtained selectively, but acid catalyzed equilibration of compound 4 to the more stable α anomer prior to coupling, which will give the α -glucuronide, can be problematic. Compound 6 was reacted with ozone to give compound 8a. Alternatively, the acetate protecting groups of compound 6 were removed by methanolysis to give compound 7, which was reacted with
15 ozone to give aldehyde 8b. Compound 8b underwent reductive amination with doxorubicin to give the prodrug 9b. Compound 8a underwent reductive amination with daunorubicin to give compound 10a, and the ester groups of compound 10a were saponified to give prodrug 10b.

20 In detail, the synthesis is as follows:

4-Pentenal diethyl acetal 5

Boron trifluoride diethyl etherate (0.2 mL) was added, with stirring, to a
25 solution of 4-pentenal (Cherif, A.; Farquhar, D. N-(5,5-diacetoxypent-1-yl)doxorubicin: A new intensely potent doxorubicin analogue. *J. Med. Chem.* **35**, 3208-3214 (1992)) (2.5 g, 29.8 mmol) in ethanol (150 mL). The mixture was refluxed for 10 min under nitrogen, then the ethanol was removed under reduced pressure. The residue was taken up in dichloromethane (25 mL), and
30 the solution was washed with 10% sodium acetate solution (15 mL) and water

(2 x 10 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and evaporated. The residue was chromatographed on a column of silica gel using chloroform/methanol (97:3) as eluent. 4-Pentenal diethyl acetal was obtained as an oil (4.5 g, 96%). ¹H NMR (CDCl₃) δ 5.88-5.61 (m, 1 H, H₄), 5.03-4.87 (m, 2 H, H₅), 4.38 (t, 1 H, J=7, H₁), 3.30-3.61 (m, 4 H, 2 x CH₂), 2.07-1.96 (m, 2 H, H₂), 1.64-1.53 (m, 2 H, H₃), 1.09 (t, 6 H, J=7, 2 x CH₃).

Methyl 1-O-[(1''RS)-1''-ethoxypent-4''-enyl]-2,3,4-tri-O-acetyl-β-D-glucopyranuronate 6

Trimethylsilyl trifluoromethanesulfonate (0.2 mL of a 0.1 M solution in chloroform; 0.02 mmol) was added, with stirring, to a solution of **5** (100 mg, 0.63 mmol) and methyl 2,3,4-tri-O-acetyl-1-O-trimethylsilyl-β-D-glucopyranuronate **4** (L. F. Tietze and R. Seele, Stereoselective synthesis of 1-O-trimethylsilyl α- and β-D-glucopyranuronate. Carbohydrate Res. **148**, 349-352 (1986)) (90.5 mg, 0.22 mmol) in dry dichloromethane (3 mL) at -70 °C under a dry nitrogen atmosphere. The mixture was kept at -70 °C for 2 days, then triethylamine (0.1 mL) was added to quench the reaction. The solvent was evaporated, and the residue was taken up in chloroform (10 mL) and washed with saturated sodium bicarbonate (10 mL) and sodium chloride (10 mL). The organic extract was dried (MgSO₄) and evaporated, and the residual solid was chromatographed on a column of silica (25 cm x 2 cm) using a stepwise gradient of hexane-ethyl acetate (10:0, 20 mL; 7:3, 100 mL; 6:4, 100 mL; 5:5, 150 mL). The eluted fractions were monitored by TLC using iodine vapor to visualize the products. The title compound was obtained as a solid. ¹H NMR (CDCl₃) δ 5.63-5.86 (m, 1 H, H₄''), 5.24-5.18 (m, 2 H, H_{3,4}), 5.05-4.99 (m, 1 H, H₂), 4.96-4.89 (m, 2 H, H₅''), 4.83-4.74 (m, 1.5 H, H₁ (S), H₁ (R), H₁'' (S)), 4.65 (t, 0.5 H, J=6.0, H₁'' (R)), 4.02-3.97 (m, 1 H, H₅), 3.71 (s, 3 H, CO₂Me), 3.68-3.43 (m, 2 H, CH₂), 1.99, 1.98, 1.96 (3 s, 9 H, 3 Ac), 1.74-1.67 (m, 2 H,

H3"), 2.09-2.01 (m, 2 H, H2"), 1.15 (t, 3 H, J=7, CH₃); MS (FAB) *m/z* 447 (M + H)⁺.

Methyl 1-O-[(1"RS)-1"-ethoxypent-4"-enyl]-β-D-glucopyramuronate 7

5

Compound 6 (72 mg, 0.167 mmol) was dissolved in dry methanol (2 mL), and 0.4 mL of a solution of sodium methoxide (42 mg, 0.78 mmol) in methanol (10 mL) was added. The reaction mixture was maintained at ambient temperature for 3 h, then evaporated under reduced pressure. The residue was
 10 purified on a thick layer of silica to give the title compound, 7, as a white solid.
¹H NMR δ 5.88-5.74 (m, 1 H, H4"), 5.07-4.90 (m, 2 H, H5"), 4.81 (t, 0.5 H, J=6.0, H1, (S)), 4.70 (t, 0.5 H, J=6.0, H1, (R)), 4.60 (d, 0.5 H, J=7.5, H1", (S)), 4.53 (d, 0.5 H, J=7.5, H1", (R)), 3.84 (s, 3 H, CO₂Me), 3.91-3.47 (m, 6 H, H2, H3, H4, H5, OCH₂CH₃), 2.13-2.05 (m, 2 H, H2"), 1.79-1.70 (m, 2 H, H3"),
 15 1.19 (t, 3 H, CH₃).

Methyl 1-O-[(1"RS)-1"-ethoxy-4"-oxobutyl-2,3,4-tri-O-acetyl-β-D-glucopyramuronate 8a

20 A solution of compound 6 (79.6 mg, 0.185 mmol) in dichloromethane (5 mL) was placed in a cylindrical gas absorption vessel with an inlet dispersion tube extending to the base. The vessel was cooled to -70 °C in a dry ice/acetone mixture, and ozone was introduced. Ozonization was continued until the reaction was complete (until the mixture turned blue as a result of formation of
 25 the ozonide, approximately 20 min). Dimethyl sulfide (54 μL, 0.74 mmol, 4 equiv) was added, and the mixture was stirred overnight to reduce the ozonide to the corresponding aldehyde. The excess dimethyl sulfide was evaporated, and the residue was chromatographed on a column of silica (23 cm x 2 cm) using a stepwise gradient of hexane-ethyl acetate (10:0, 50 mL; 7:3, 150 mL;
 30 6:4, 100 mL). 100 fractions of approx. 3 mL each were collected. The major

product (fractions 62-67) was identified by NMR as the title compound. ¹H NMR (CDCl₃) δ 9.72 (s, 1 H, CHO), 5.25-5.18 (m, 2 H, H3,4), 5.09-5.01 (m, 1 H, H2), 4.85-4.75 (m, 2 H, H1 (R,S), H1" (R,S)), 4.02-3.97 (m, 1 H, H5), 3.73 (s, 3 H, CO₂Me), 3.65-3.39 (m, 2 H, CH₂), 2.57-2.51 (m, 2 H, H3"), 1.98-1.92 (m, 2 H, H2"), 2.03, 2.02, 2.00 (3 s, 9 H, 3 Ac), 1.16 (t, 3 H, J=7, CH₃).

Methyl 1-O-[(1"RS)-1"-ethoxy-4"-oxobutyl]-β-D-glucopyranuronate 8b

A solution of compound 7 (56.3 mg, 0.185 mmol) in dichloromethane (15 mL) was ozonized for 20 minutes, as described for 8a. The intermediate ozonide was reduced with dimethyl sulfide (54 μL, 0.74 mmol, 4 equiv). The product was purified by preparative chromatography on silica.

N-[(4"RS)-4"-Ethoxy-4"-(methyl 2""", 3""", 4"""-tri-O-acetyl-β-D-glucopyranuronyloxy)butyl]doxorubicin hydrochloride 9a

A solution of sodium cyanoborohydride (1 M in tetrahydrofuran; 11.3 μL, 0.0113 mmol) was added to a stirred solution of doxorubicin hydrochloride (10 mg, 0.017 mmol) and compound 8a (15 mg, 0.035 mmol) in acetonitrile-water (2:1) (5 mL). The mixture was stirred under a nitrogen atmosphere at room temperature in the dark for 1 h. When reaction was complete (as evidenced by TLC of a 5 μL aliquot), the solution was diluted with water (8 mL), and extracted repeatedly (10 x 10 mL) with chloroform-methanol (5:1). The combined extracts were dried and evaporated to give a red amorphous solid which was purified by preparative TLC (chloroform-methanol, 10:1). The yield was 8.2 mg (51%). The product was suspended in water (1 mL), and acidified to pH 5 by dropwise addition of 0.05 N hydrochloric acid. The solution was lyophilized to afford the title compound which was stored under nitrogen in a tightly stoppered vessel at -78 °C in the dark. ¹H NMR (CDCl₃) (free base) δ 7.90 (m, 1 H, H1), 7.71 (t, J=8, 1 H, H2), 7.34 (m, 1 H, H3), 5.53-5.10 (m, 5 H,

H7, H1", H2"', H3''', H4''''), 4.87-4.30 (m, 4 H, H4" (R,S), H1'''' (R,S),
 H14), 4.05-3.90 (m, 1 H, H5'''''), 4.02 (s, 3 H, 4-CH₃), 3.75-3.36 (m, 4 H, H4",
 H5", OCH₂CH₃), 3.71 (s, 3 H, CO₂Me), 3.25-2.50 (m, 5 H, H10a, H10b, H3",
 H1"), 2.4-2.2 (m, 2 H, H8a, H8b), 2.04-2.02 (3 s, 9 H, 3 Ac), 2.0-1.5 (m, 6 H,
 5 H2", H3", H2"a, H2"b), 1.36 (d, J=6, 3 H, H6"), 1.13-1.05 (m, 3 H, OCH₂CH₃).

*N-[(4"RS)-4"-Ethoxy-4''-(methyl β-D-glucopyranuronyloxy)butyl]doxorubicin
 hydrochloride 9b*

10 1 M sodium cyanoborohydride (20 μL, 0.02 mmol) was added to a
 solution of compound **8b** (12 mg, 0.039 mmol) and doxorubicin hydrochloride
 (22 mg, 0.038 mmol) in acetonitrile-water (2:1) (5 mL) under nitrogen. The
 mixture was stirred at room temperature in the dark for 2 h. When reaction was
 complete [as evidenced by TLC of a 5 μL aliquot using chloroform-methanol
 15 (9:2) as eluent or HPLC on a C-18 column using 0.05 M ammonium acetate-
 acetonitrile (6:4) as mobile phase], the solution was diluted with water (8 mL),
 and then extracted repeatedly (10 x 10 mL) with chloroform-methanol (5:1).
 The combined extracts were dried and evaporated to give a red amorphous solid.
 Preparative TLC of this solid (chloroform-methanol, 7:3) afforded three bands.
 20 The fastest moving band was shown by NMR and MS to be the desired product.
 Yield 16.8 mg (53%). The compound was suspended in water (1 mL), and
 acidified to pH 5 by dropwise addition of 0.05 N hydrochloric acid. The
 solution was lyophilized to afford the title compound. ¹H NMR (CD₃OD) (free
 base) δ 7.86 (m, 1 H, H1), 7.82 (t, 1 H, H2), 7.57 (m, 1 H, H3), 5.49-5.44 (m, 1
 25 H, H1"), 5.07-5.03 (m, 1 H, H7), 4.9-4.2 (m, 4 H, H4" (R,S), H1'''' (R,S),
 H14), 4.03 (s, 3 H, 4-CH₃), 3.85-3.65 (m, 7 H, H2''''', H3''''', H4''''', H5''''',
 CO₂Me), 3.65-3.15 (m, 4 H, H4", H5", OCH₂CH₃), 3.15-2.55 (m, 5 H, H10a,
 H10b, H3", H1"), 2.4-1.9 (m, 6 H, H8a, H8b, H2"a, H2"b, H3"), 1.8-1.6 (m, 2
 H, H2"), 1.30 (d, J=6, 3 H, H6"), 1.18-1.08 (m, 3 H, OCH₂CH₃). MS (FAB) *m/z*
 30 850 (M + H)⁺.

N-[(4''RS)-4''-Ethoxy-4''-(methyl 2''''', 3''''', 4'''''-tri-O-acetyl-β-D-glucopyranuronyloxy)butyl]daunorubicin hydrochloride 10a

5 A solution of sodium cyanoborohydride (1 M in tetrahydrofuran; 11.3 μL, 0.0113 mmol) was added to a stirred solution of daunomycin hydrochloride (9.6 mg, 0.017 mmol) and compound 8a (15 mg, 0.035 mmol) in acetonitrile-water (2:1) (5 mL). The mixture was stirred under a nitrogen atmosphere at room temperature in the dark for 1 h. When reaction was complete, the solution
10 was diluted with water (8 mL), and extracted repeatedly (10 x 10 mL) with chloroform-methanol (5:1). The product was purified by thick layer chromatography using chloroform-methanol (9:1) as eluent. Yield, 9.0 mg (55%). ¹H NMR (CDCl₃) (free base) δ 8.92 (d, 1 H, J=8, H1), 7.76 (t, J=8, 1 H, H2), 7.37 (d, 1 H, J=8, H3), 5.53 (br. s, 1 H, H1''), 5.35-4.93 (m, 4 H, H2''', H3''''', H4''''', H7), 4.82-4.40 (m, 2 H, H4'' (R,S), H1'''' (R,S)), 4.20-4.0 (m, 1 H, H5'''''), 4.03 (s, 3 H, 4-CH₃), 3.8-3.3 (m, 4 H, H4'', H5'', OCH₂CH₃), 3.69 (s, 3 H, CO₂Me), 3.3-2.6 (m, 5 H, H10a, H10b, H3'', H1''), 2.40 (s, 3 H, 14-CH₃), 2.00-1.98 (3 s, 9 H, 3 Ac), 2.5-1.9 (m, 4 H, H8a, H8b, H3''), 1.9-1.5 (m, 4 H, H2'', H2''a, H2''b), 1.32 (d, J=6, 3 H, H6''), 1.19-1.09 (m, 3 H, OCH₂CH₃).

20

N-[(4''RS)-4''-Ethoxy-4''-(β-D-glucopyranuronyloxy)butyl]daunorubicin (Sodium salt) 10b

0.1 N NaOH solution (2.0 mL) was added to a solution of compound
25 10a (8 mg, 8.0 μmol) in methanol (2.0 mL). The reaction mixture was maintained for 1 h at ambient temperature. It was then added to a column of Amberlite IRC-50 CP cation exchange resin in the H⁺ form (500 mg, 11.3 meq/g). The column was washed with water and the eluent was collected in a flask containing 0.1 M triethylammonium acetate (3 mL, pH 7) that was
30 maintained at 0 °C. After all the colored material had eluted, the contents of the

flask were frozen and lyophilized. The residual red powder was taken up in water, and the solution was applied to a column of weakly basic cation exchange resin (Biorex 70- Na^+ ; 235 mg). The product was eluted with water. The eluent was frozen and lyophilized to afford the title compound which was
5 characterized by mass spectrometry. Yield, 4.5 mg (67%). MS (FAB, glycerol) m/z 886 $[\text{M} - 2\text{H} + 3\text{Na}]^+$, 864 $[\text{M} - \text{H} + 2\text{Na}]^+$, 842 $[\text{M} + \text{Na}]^+$, 820 $[\text{M} + \text{H}]^+$.

Example 3: Synthesis of Glucuronide Prodrugs of the Invention.

10 The compounds referred to in this synthesis are shown in Figure 7. The numbered intermediates of the Figure are cross-referenced in the text below in bold.

Acetal **6** was prepared in two unexceptional steps from alcohol **4**, and
15 was reacted with silyl glycoside **3** to give compound **7** using the method described by Tietze, et al. (*Carbohydrate Res.*, Vol. 180 (1988), 253-262). Alkenes such as **7** can be reacted with anthracyclines such as **10** to form the prodrugs following published procedures involving ozonolysis, reductive amination, and deacetylation (A. Cherif, D. Farquhar, *J. Med. Chem.*, Vol. 35
20 (1992), 3208-3214). The glucuronyl hydroxyls were deprotected before ozonolysis and reductive amination. methanolysis using catalytic NaOMe gave alkene **8** in good yield. Reductive alkylation of the amino group of **10** by aldehyde **9** (obtained by ozonolysis of alkene **8**) using NaBH_4 or NaBH_3CN as a reducing agent gives the prodrug **11**. Finally, mild enzymatic hydrolysis of the
25 methyl ester of compound **11** affords prodrug **12**. Deesterification can be carried out in vitro, and compound **12** should be stored as the salt of the acid; the acid form is expected to undergo autocatalyzed decomposition. Alternatively, compound **11** can be used as a pre-prodrug, and esterase-catalyzed hydrolysis will occur in vivo.

In detail, the synthesis is as follows:

6,6-Dimethoxy-1-hexene 6

5 A solution of 5-hexen-1-ol **4** (5.0 g, 50 mmol) in 25 mL of CH_2Cl_2 was added dropwise to a rapidly stirred suspension of PCC (21.5 g, 100 mmol) in 200 mL of CH_2Cl_2 cooled by an ice bath. After the addition was complete, the mixture was allowed to warm to room temperature. After 3 h, approximately 20 g of silica gel was added to the dark, tarry mixture, and then the mixture was
10 diluted with 200 mL of ether. Then, the mixture was filtered through a pad of silica gel, eluting with an additional 400 mL of ether. The solvents were removed by distillation to leave 5.7 g of a pale yellow liquid, which contained residual ether, CH_2Cl_2 , 5-hexenyl 5-hexenoate as well as 5-hexenal, compound **5**. ^1H NMR (CDCl_3) δ 1.69-1.79 (m, 2, $\text{CH}_2\text{CH}_2\text{CH}_2$), 2.04-2.14 (m, 2,
15 $\text{CH}_2\text{CH}=\text{CH}_2$), 2.45 (dt, 2, $J=1.6, 7.3$, CH_2CHO), 4.97-5.06 (m, 2, $\text{CH}=\text{CH}_2$), 5.77 (dddd, 1, $J=6.7, 6.7, 10.2, 17.0$, $\text{CH}=\text{CH}_2$), 9.77 (t, 1, $J=1.6$, CHO); ^{13}C NMR (CDCl_3) δ 21.15, 32.92, 43.07, 115.53, 137.52, 202.46.

The above oxidation can also be carried out using N-methylmorpholine
20 N-oxide (NMO) and catalytic tetrapropylammonium perruthenate (TPAP) in CH_2Cl_2 , moderating the vigorous reaction by cooling with an ice bath.

The crude product containing compound **5** was taken up in 30 mL of MeOH, and camphorsulfonic acid (596 mg, 2.5 mmol) and trimethyl
25 orthoformate (5.46 mL, 50 mmol) were added. The mixture was heated at reflux for 3 h, then allowed to stand at room temperature overnight. The acid was neutralized by the addition of 0.70 mL of triethylamine, and most of the solvent was removed by distillation. The residue was partitioned between water and hexane, the hexane layer was dried over anhydrous Na_2SO_4 , and the
30 solution was filtered through a 3 in column of silica gel, eluting with additional

hexane. The solvent was removed by distillation to leave 5.0 g of the product, compound 6, as a colorless liquid. ^1H NMR (CDCl_3) δ 1.39-1.49 (m, 2), 1.58-1.65 (m, 2), 2.03-2.11 (m, 2), 3.31 (s, 6, $\text{CH}(\text{OCH}_3)_2$), 4.37 (t, 1, $J=5.7$, $\text{CH}(\text{OCH}_3)_2$), 4.93-5.05 (m, 2, $\text{CH}=\text{CH}_2$), 5.80 (dddd, 1, $J=6.6, 6.6, 10.3, 16.9$, $\text{CH}=\text{CH}_2$); ^{13}C NMR (CDCl_3) δ 23.79, 31.83, 33.42, 52.49, 104.33, 114.64, 138.38.

Methyl 2,3,4-tri-O-acetyl-1-O-(R,S-1-methoxy-5-hexenyl)- β -D-glucuronate 7

- 10 A 0.1 M solution of trimethylsilyl trifluoromethanesulfonate in CH_2Cl_2 (0.1 equiv.) was added to a mixture of crude silyl ether 3 (1 equiv., see Example 1 for its preparation) and 1,1-dimethoxy-5-hexene 6 (1 equiv.) in CH_2Cl_2 (0.1 M) cooled to -78°C . After three days, the trimethylsilyl trifluoromethanesulfonate was neutralized by adding triethylamine (1 equiv.).
- 15 one volume of ether was added, the solution was warmed to room temperature, filtered through a pad of silica gel with ether, and the filtrate was concentrated in vacuo. Purification by flash chromatography (2% triethylamine in 30-40-70% ethyl acetate:hexane) resulted in the elution of, in order, recovered alkene, α -silyl glucuronide, desilylated glucuronate, and the product 6 as a 2.5:1
- 20 mixture of diastereoisomers. ^1H NMR (CDCl_3) δ 1.26-1.37 (m, 2), 1.45-1.57 (m, 2), 1.87-2.00 (m, 11), 3.16 (s, 3, CHOCH_3 of major isomer), 3.24 (s, 3, CHOCH_3 of minor isomer), 3.60 (s, 3, COOCH_3 of minor isomer), 3.60 (s, 3, COOCH_3 of major isomer), 3.96 (d, 1, $J=9.4$, H5), 4.45 (t, 1, $J=5.5$, CHOCH_3 of minor isomer), 4.65 (t, 1, $J=5.5$, CHOCH_3 of major isomer), 4.65-4.67 (H1 of minor isomer partially obscured), 4.74 (d, 1, $J=7.8$, H1 of major isomer),
- 25 4.78-4.83 (m, 2, $\text{CH}=\text{CH}_2$), 4.86-4.92 (m, 1, H2), 5.03-5.10 (m, 1, H4), 5.10-5.17 (m, 1, H3), 5.63 (dddd, 1, $J=3.0, 9.9, 14.0, 16.8$, $\text{CH}=\text{CH}_2$); ^{13}C NMR (CDCl_3) δ 20.15, 22.98, 23.20, 32.15, 32.91, 32.99, 33.60, 51.74, 52.32, 54.48, 69.12, 70.97, 72.09, 96.12, 102.12, 105.28, 114.41, 138.00, 166.73, 166.82,
- 30 168.63, 168.91, 169.62.

Methyl 1-O-(R,S-1-methoxy-5-hexenyl)-β-D-glucuronate 8

To a solution of triacetate 7 (474 mg, 1.06 mmol) in 10 mL of MeOH was added 25 wt % NaOMe in MeOH (0.03 mL). After 1 h, excess ammonium acetate was added to neutralize the mixture. The volatile components were evaporated in vacuo, and the residue was purified by flash chromatography (2% triethylamine in ethyl acetate) to give 304 mg of the product as a colorless oil (89%). R_f 0.28 (2% triethylamine/ethyl acetate); ^1H NMR (CDCl_3) δ 1.39-1.59 (m, 2, H_3'), 1.61-1.68 (m, 2, H_2'), 2.00-2.07 (m, 2, H_4'), 3.23-3.28 (m, 1, H_2), 3.34-3.42 (m, 1, H_3), 3.37 (s, 3, CHOCH_3 of major isomer), 3.38 (s, 3, CHOCH_3 of minor isomer), 3.50-3.57 (m, 1, H_4), 3.75 (s, 3, COOCH_3 of minor isomer), 3.76 (s, 3, COOCH_3 of major isomer), 3.83 (d, 1, $J=9.7$, H_5 of minor isomer), 3.84 (d, 1, $J=9.7$, H_5 of major isomer), 4.46 (d, 1, $J=7.8$, H_1 of minor isomer), 4.56 (d, 1, $J=7.8$, H_1 of major isomer), 4.56-4.60 (m, 1, CHOCH_3 of minor isomer), 4.72 (t, 1, $J=5.6$, CHOCH_3 of major isomer), 4.90-5.01 (m, 2, $\text{CH}=\text{CH}_2$), 5.78 (dddd, 1, $J=6.7, 6.7, 10.2, 16.9$, $\text{CH}=\text{CH}_2$); ^{13}C NMR (CDCl_3) δ 24.59 (C_3' major), 24.75 (C_3' minor), 34.44 (C_4' major), 34.56 (C_2' major, C_4' minor), 35.36 (C_2' minor), 52.78 (COOCH_3), 53.48 (CHOCH_3 major), 55.72 (CHOCH_3 minor), 73.06 (C_4), 74.71 (C_2 minor), 74.76 (C_2 major), 76.74 (C_5), 77.34 (C_3 major), 77.39 (C_3 minor), 100.82 (C_1 minor), 101.73 (C_1 major), 104.49 (C_1' major), 106.99 (C_1' minor), 115.02 (C_6'), 139.75 (C_5'), 171.11 (COOCH_3).

Methyl 1-O-(R,S-1-methoxy-5-oxopentyl)-β-D-glucuronate 9

25

Ozone was bubbled through a solution of alkene 8 (45 mg) in 20 mL of MeOH cooled by a dry ice/acetone bath until a persistent blue color was observed. Excess ozone was purged by bubbling nitrogen through the mixture, and 3 mL of dimethyl sulfide was added to the mixture. After 5 h, the volatile components were evaporated in vacuo. Examination of the residue by ^1H NMR,

30

indicated that the vinyl protons were absent, but no aldehydic protons were observed. The residue was taken up in 10 mL of 1:1 ethyl acetate and CH_2Cl_2 , and 100 mg of anhydrous Na_2SO_4 and 2 mL of dimethyl sulfide were added. After standing at room temperature for 3 days, the mixture was filtered through
 5 a pad of silica gel, eluting further with ethyl acetate. The volatile components were evaporated in vacuo, and examination of the ^1H NMR spectrum indicated the presence of the aldehydic protons. Partial ^1H NMR (CDCl_3) δ 1.61-1.71 (m, 4, $\text{CH}_2\text{CH}_2\text{CH}_2\text{CHO}$), 2.41 (CH_2CHO of major isomer), 2.56 (CH_2CHO of minor isomer), 3.38 (s, 3, CHOCH_3 of major isomer), 3.45-3.50 (m, 1, H2),
 10 3.58-3.64 (m, 1, H3), 3.71-3.77 (m, 1, H4), 3.79 (s, 3, COOCH_3 of minor isomer), 3.80 (s, 3, COOCH_3 of major isomer), 3.90 (d, 1, $J=9.6$, H5), 4.52 (d, 1, $J=7.8$, H1 of minor isomer), 4.66 (d, 1, $J=7.7$, H1 of major isomer), 4.75 (bs, 1, CHOCH_3 of major isomer), 9.74 (s, 1, CH=O of major isomer), 9.77 (s, 1, CH=O of minor isomer).

15

Reductive alkylation of doxorubicin 10 by aldehyde 9

Solid NaBH_4 (0.7 equiv.) is added to a 0.01 M solution of doxorubicin hydrochloride 10 in 2:1 $\text{MeOH:H}_2\text{O}$ containing aldehyde 9 (2 equiv.). The
 20 mixture is stirred in the dark under argon at room temperature until the starting material is consumed as observed by TLC. The solution is diluted with 1.5 volumes of H_2O and extracted repeatedly with 5:1 $\text{CHCl}_3/\text{MeOH}$. The organic phases are dried over anhydrous Na_2SO_4 and concentrated in vacuo. The product, compound 11, is purified by reverse phase HPLC (125 mM Et_3N -
 25 HOAc in H_2O (pH 7)/ MeOH), repeated lyophilization to remove excess buffer salts, and ion exchange on DEAE-Sepharose (HCl form).

Hydrolysis of compound 11 to give compound 12

Pig liver esterase (130 U) is added to a 0.1 M solution of ester 11 in 0.1 M sodium phosphate buffer (pH 7.5) at 33 °C. After 5 h, the mixture is filtered through a membrane filter, and the product 12 is purified from the filtrate chromatographically.

5

Example 4: Prodrug Enzyme Activation.

Enzymes. β -Glucuronidase (E. Coli) (EC 3. 2. 1. 31) was purchased from Sigma Chemical Co., St. Louis, MO and was used as received. The specific
10 activity of the preparation was 16,000 units/mg protein, where 1 unit is defined as the amount of enzyme that will liberate 1.0 μ g of phenolphthalein from phenolphthalein β -glucuronide per hour at pH 6.8 and 37°C.

**Stability Studies of *N*-[*(4''RS)*-4''-Ethoxy-4''-(*B-D*-
15 *glucopyranurongloxy*)butyl] daunorubicin (sodium salt) 10b in the presence of β -glucuronidase.** The title compound (in the form of its sodium salt) (16.8 μ g; 0.02 μ mol) was dissolved in 0.05 M potassium phosphate buffer, pH 7.4 (200 μ L) contained in a 2.0-mL glass vial (final drug concentration 10^{-4} M). The solution was incubated at 37°C for 50 h. At selected time intervals (1, 4, 8,
20 12, 24, 30, and 50 h) aliquots (10 μ L) were withdrawn and analyzed for parent drug by HPLC on a C-18 reverse-phase column (Waters Associates, Milford, MA; μ -Bondapak C-18; 200 x 4.6 mm, i.d.). A solution of CH₃CN-0.05M acetate buffer, pH 4.0 (2:3; v/v), at a flow rate of 1.0 mL/min, was used as mobile phase. (retention time = 3.91 min).

25

For the enzyme studies, 10b (33.6 μ g; 0.04 μ mol) and sodium cyanide (9.8 μ g; 0.2 μ mol) were dissolved in 0.05 M potassium phosphate buffer, pH 7.4 (380 μ L) contained in a 2.0-mL glass vial (final drug concentration 10^{-4} M). The reaction was initiated by the addition of 28 units of β -glucuronidase (2.2
30 units of enzyme per μ mole of substrate) in the same buffer (20 μ L). At

intervals of 0.25, 0.5, 2, 5, 8, 24, and 32 h, aliquots (20 μ L) of the mixture were withdrawn and added to 4 volumes of MeOH contained in 1.5-mL centrifuge tubes. The tubes were agitated on a Vortex shaker for 20 s and then centrifuged for 4 min at 1000 rpm. Aliquots (25 μ L) of the clear supernatant were analyzed
5 by HPLC as described above. The peak corresponding to the parent compound gradually disappeared and was replaced by two peaks with retention times of 6.58 and 7.08, respectively. The experiment was repeated in the presence of 10 units and 20 units of the enzyme per μ mol of substrate. The half-lives for the disappearance of **10b**, determined by linear least-square regression analysis of
10 the pseudo first-order reactions were 2-fold enzyme excess, 8.1 h; 10-fold enzyme excess, 6.9 h; 20-fold enzyme excess, 2.0 h.

Growth Inhibition Studies Six cell lines: A-375 (human melanoma), LS174T
15 (colon carcinoma), ME 180 (cervical carcinoma), SK-OV-3 (ovarian carcinoma), and BT-474 (breast carcinoma) were routinely grown in Hank's Minimal Essential Medium (MEM, Gibco Inc.) containing 10 % fetal bovine serum albumin (Atlanta Biologics). Cells were passaged weekly by trypsinization (Gibco) followed by plating at reduced density (50,000 cells/ml).
20 They were routinely tested and found to be free of mycoplasma contamination. Cells were harvested by trypsinization and plated in 96 well plates at a density of 5,000 per well in 100 μ l of MEM culture media. Cells were allowed to adhere by incubation for 24 hr at 37°C in humidified 5% CO₂. The wells containing log-phase cells were treated with complete MEM containing serial
25 dilutions of N-[(4"R)-4"-Ethoxy-4"- β -D-glucopyranuronyloxy)butyl] daunorubicin (sodium salt) 10b at concentrations ranging from 10⁻⁵ to 10⁻¹⁴M. Each well also contained a 50-fold unit excess of β -glucuronidase (i.e., 50 units of enzyme per μ mole of substrate). Control actions were run with **10b** in the absence of β -glucuronidase, daunomycin alone, and daunomycin in the
30 presence β -glucuronidase. The cells were then incubated for a further 72 hr at

37°C in a humidified CO₂ incubator. The wells were emptied and the remaining cells were stained by the addition of 100 µl of 0.5% Crystal Violet (Fischer Scientific) in 20% methanol (Fischer Scientific). After incubation for 20 min, the dye was removed, and the wells were washed with deionized water. Cell-bound dye was solubilized with Sorenson's Buffer (0.1 M sodium citrate, pH 4.2-ethanol, 1:1, v/v) and the wells were read on an ELISA microplate autoreader at 540 nm. Dose-response curves were constructed and the IC₅₀ values (the drug concentrations that inhibited cell growth by 50%) determined.

10

With the A375 cell line the IC₅₀ for the glucuronide was 2×10^{-7} g/ml. In the presence of glucuronidase, the IC₅₀ was 2×10^{-11} g/ml demonstrating the potency of these compounds as prodrugs on specific activation.

15 Example 5: Endogenous Enzyme Activation of Prodrugs in Animal Models.

The studies in animals followed protocols similar to those seen with the cell lines used for *in vivo* studies are colon carcinoma cell lines LS174T (ATCC CL 188), Colo 205 (ATCC CCL 222), Lovo (ATCC CCL 229), Cx1, Mx1, B16, CU38, and H. Tumor cells were implanted as sub-cutaneous injection of 3×10^6 for LS174T and allowed to grow to desired size typically a tumor volume of 20-100 mm³ ($L \times W^2/2$) in about 4-8 days from sub-cutaneous injection of the tumor cell lines into the nude mice (NCR nude mice female 6-9 week, Taconic Farms Inc. or Jackson Labs). The Cx1, and Mx1 tumors were transplanted by insertion of 1-10mm³ subcutaneously. The mouse tumors LL (lewis lung) and Cu38 colon C-38 were carried in BDF1 mice. The tumor volumes were calculated based on caliper measurements. In any given study there are 10 animals in the control group and 5-10 in the treatment groups. Animals were treated with prodrug in the range of 0.5-50 mg/kg/day with treatment schedules from 3 to 12 days of consecutive IV treatments.

α Tumor size was monitored also at 2-4 day intervals. In a parallel set of animals, the pH of the tumor was also modified by the use of IP injections of D-glucose (4.5mg/g) and Na HCO₃ (0.33mg/g) these were then dosed with prodrug after 40 min with 0.5-50 mg/kg/day. This cycle of glucose/NaHCO₃ followed by prodrug would be repeated daily for 3-12 days of treatment as in the prodrug only group.

The animals in the study after final prodrug treatment were monitored for up to 60 days. The results demonstrated significant reduction of tumor growth for treated animals. At the end of the experiment the tumor mass was also measured by excision of the tumor mass.

Example 6: Exogenous Enzyme Activation of Prodrugs in Animal Models.

15

The studies in animals basically followed those of Meyer DL et al (Cancer Res 1993 53, 3956-3963). The cell lines used for the in vivo studies were colon carcinoma cell lines LS174T (ATCC CL 188), Colo 205 (ATCC CCL 222) and Lovo (ATCC CCL 229). Tumor cells were implanted as sub-cutaneous injection of 3×10^6 for LS174T and allowed to grow to the desired size typically a tumor volume of 20-100 mm³ (L X W/2) in about 4-8 days from sub-cutaneous injection of the tumor cell lines into the nude mice (NCR nude mice female 6-9 week, Taconic Farms Inc. or Jackson Labs). The tumor volumes were calculated based on caliper measurements. In any given study, there were 10 animals in the control group, and 5-10 in the treatment group. Animals were treated enzyme doses at 55-500 μg per mouse some with repeated doses of up to three separate treatments. Typically, enzyme was dosed at day 4-8, with a time interval of 4-12 days between the enzyme doses. The prodrug treatment was normally applied at 3-10 days after the enzyme injection. Prodrug doses were in the range of 0.5-50 mg/kg/day.

Tumor size was monitored also at 2-4 day intervals. In a parallel set of animals, the pH of the tumor was also modified by the use of IP injections of D-glucose (4.5 mg/g) and Na HCO₃ (0.33 mg/g) these were then dosed with prodrug after 40 min with 0.5-50 mg/kg/day. This cycle of glucose/NaHCO₃ followed by prodrug was repeated daily for 3-10 days of treatment. The animals in the study were monitored for up to 60 days at 7 day intervals.

The results demonstrated significant reduction of tumor growth for animals treated with the enzyme followed by prodrug both with pH modulation by the glucose infusion protocol. At the end of the experiment the tumor mass was also measured by excision of the tumor mass.

Example 7: Targeted Antibody-Enzyme Activation of Prodrugs in Animal Models.

15

The studies in animals basically followed those of Meyer DL et al (Cancer Res 1993 53, 3956-3963). The cell lines used for *in vivo* studies were colon carcinoma cell lines LS174T (ATCC CL 188), Colo 205 (ATCC CCL 222) and Lovo (ATCC CCL 229). Tumor cells were implanted by sub-cutaneous injection of 3×10^6 for LS174T and allowed to grow to the desired size, typically, a tumor volume of 20-100 mm (L X W²/2) in about 4-8 days from sub-cutaneous injection of the tumor cell lines into the nude mice (NCR nude mice female 6-9 week, Taconic Farms Inc. or Jackson Labs.) The tumor volumes were calculated based on caliper measurements. In any given study 10 animals were the control group, and 5 in treatment group. Animals were treated with specific (anti-TAG-72, anti CEA antibody fusions) and also non-specific (anti NP antibody fusion) at various time points with antibody-enzyme doses at 35-280 µg per mouse some with repeated doses up to three separate treatments. Typically, antibody was dosed at day 4-81, with a time interval of 4-12 days between the antibody doses. The prodrug treatment was normally applied at 3-

10 days after the antibody injection. Prodrug doses were in the range of 0.5-50 mg/kg/day.

Tumor size was monitored also at 2 day intervals. In a parallel set of
5 animals the pH of the tumor was also modified by the use of IP injections of D-glucose (4.5 mg/g) and Na HCO₃ (0.33 mg/g) these were then dosed with prodrug after 40 min with 0.5-50 mg/kg/day. This cycle of glucose/NaHCO₃ followed by prodrug was repeated daily for 3-10 days of treatment.

10 The animals in the study were monitored for up to 60 days at 7 day intervals. The results demonstrated significant reduction of tumor growth for animals treated with the specific antibody followed by prodrug both with and without pH modulation by the glucose infusion protocol. At the end of the experiment the tumor mass was also measured by excision of the tumor mass.


15

* * *

The foregoing is intended as illustrative of the present invention but not limiting. Numerous variations and modifications may be effected without departing from the true spirit and scope of the invention.

WHAT IS CLAIMED IS:

1. A compound of the formula



where:

R^1 is a radical of an anthracyclinone where the point of attachment is the
 10 3' nitrogen of the daunosamine sugar;

R^2 is H, alkyl having from 1 to 6 carbon atoms, phenyl or aromatic or
 heteroaromatic having from 1 to 10 carbon atoms substituted with NO_2 , CN, F,
 Cl, OH, OMe, or alkoxy having from 1 to 6 carbon atoms, COMe, CF_3 , COOH,
 COO(alkyl or aryl) having from 1 to 10 carbon atoms;


15 R^3 is cyano, methoxy, ethoxy, alkoxy having from 3 to 18 carbon atoms,
 phenoxy or aryloxy having from 1-10 carbon atoms substituted with NO_2 ,
 CN, F, Cl, OH, alkoxy having from 1 to 6 carbon atoms, COMe, CF_3 , COOH,
 or COO (alkyl or aryl) having from 1 to 10 carbon atoms, acetoxy,
 propionyloxy, trimethylacetoxo, or benzoyloxy;

20 $X = \text{CH}_2$, O, S, or N substituted by H, alkyl or acyl having from 1 to 6
 carbon atoms, phenyl, or aromatic or heteroaromatic having from 1 to 10 carbon
 atoms substituted with methyl, ethyl, acetyl or benzoyl;

$n = 2$ if $X = O, S,$ or substituted N ;

$n = 1$ or 2 if $X = CH_2$;

B is $O, NHCOO,$ or one of the following substituted aromatics:



where M is $H, NO_2, CN, F, Cl, OH,$ alkoxy having from 1 to 18 carbon atoms,

10 $COMe, CF_3, COOH, COO(alkyl \text{ or } aryl)$ having from 1 to 10 carbon atoms,

phenyl, aromatic or heteroaromatic having from 1 to 10 carbon atoms, methyl or

alkyl having from 2 to 18 carbon atoms; and

Z is a glycosyl, or substituted aliphatic or aromatic alkyl or acyl having

from 1 to 18 carbon atoms attached to the aromatic or carbamoyl O of B at the

15 anomeric carbon of Z ;

provided that where R^3 is aryloxy or acyloxy, BZ cannot be the same as


R^3 .

2. A compound as in claim 1 wherein said anthracyclinone is

20 doxorubicin or daunorubicin.

3. A compound as in claim 1 wherein Z is galactosyl, glucuronyl or salt or ester having 1 to 4 carbon atoms, thereof.
4. A compound as in claim 1 wherein R² is a phenyl, thiophenyl, or pyridinyl substituted with NO₂, F, OMe, or CF₃.
5. A compound as in claim 1 wherein R³ is an aryloxy having from 1-6 carbon atoms, substituted with NO₂, F, OMe, or CF₃.
- 10 6. A compound as in claim 1 wherein X is an O or an N substituted with a methyl, ethyl, or phenyl.
7. A compound as in claim 1 wherein M is alkoxy having from 1-3 carbon atoms or COO (alkyl or aryl) having from 1-3 carbon atoms or alkyl
15 having from 1-3 carbon atoms.
8. A compound as in claim 1 wherein from 1-4 Ms are substituted on the ring.
- 20 9. A compound as in claim 1 wherein Z is an aliphatic or aromatic alkyl or acyl having from 1-7 carbon atoms.

10. A compound of the formula



5


where

R^1 is a radical of an anthracycline such as doxorubicin, daunorubicin or a derivative thereof where the point of attachment is the 3' nitrogen of the daunosamine sugar:

10 $n = 1$ or 2 ;

R^2 is H, alkyl having from 1 to 6 carbon atoms, phenyl or aromatic or heteroaromatic having from 1 to 10 carbon atoms substituted with NO_2 , CN, F, Cl, OH, OMe, or alkoxy having from 1 to 6 carbon atoms, COMe, CF_3 , COOH, COO(alkyl or aryl) having from 1 to 10 carbon atoms;

15 B is O, NHCOO, or one of the following substituted aromatics:




where M is H, NO₂, CN, F, Cl, OH, alkoxy having from 1 to 18 carbon atoms, COMe, CF₃, COOH, COO(alkyl or aryl) having from 1 to 10 carbon atoms, phenyl, aromatic or heteroaromatic having from 1 to 10 carbon atoms, methyl or alkyl having from 2 to 18 carbon atoms; and

5 Z is a glycosyl, or substituted aliphatic or aromatic alkyl or acyl having from 1 to 10 carbon atoms, attached to the aromatic or carbamoyl O of B at the anomeric carbon of Z.

11. A compound as in claim 10 wherein Z is a galactosyl or glucuronyl
10 or salt or ester having 1 to 4 carbon atoms, thereof.

12. A compound of the formula

15



where:

20

B is O or NHCOO;

R^1 is a radical of an anthracyclinone such as doxorubicin, daunorubicin or a derivative thereof where the point of attachment is the 3' nitrogen of the daunosamine sugar;

$n = 1$ or 2 ;

5 R^2 is H, alkyl having from 1 to 6 carbon atoms, phenyl or aromatic or heteroaromatic having from 1 to 10 carbon atoms substituted with NO_2 , CN, F, Cl, OH, OMe, or alkoxy having from 1 to 6 carbon atoms, COMe, CF_3 , COOH, COO(alkyl or aryl) having from 1 to 10 carbon atoms;

M is NO_2 , CN, F, Cl, OH, alkoxy having from 1 to 18 carbon atoms, 10 COMe, CF_3 , COOH, COO(alkyl or aryl) having from 1 to 10 carbon atoms, phenyl, aromatic or heteroaromatic having from 1 to 10 carbon atoms, methyl or alkyl having from 2 to 18 carbon atoms; and

Z is a glycosyl, or substituted aliphatic or aromatic acyl having from 1 to 18 carbon atoms, attached to the carbamoyl O of B at the anomeric carbon of Z.


15

13. A compound as in claim 12 wherein Z is a galactosyl or glucuronyl or salt or ester having 1 to 4 carbon atoms, thereof.

14. A compound of the formula

20

51



where

5 R^1 is a radical of an anthracyclinone such as doxorubicin, daunorubicin or a derivative thereof where the point of attachment is the 3' nitrogen of the daunosamine sugar;

$n = 1$ or 2 ;

R^2 is H, alkyl having from 1 to 6 carbon atoms, phenyl or aromatic or
10 heteroaromatic having from 1 to 10 carbon atoms substituted with NO_2 , CN, F, Cl, OH, OMe, or alkoxy having from 1 to 6 carbon atoms, COMe, CF_3 , COOH, COO(alkyl or aryl) having from 1 to 10 carbon atoms;

B is O or NHCOO ;


M is H, NO_2 , CN, F, Cl, OH, alkoxy having from 1 to 18 carbon atoms,
15 COMe, CF_3 , COOH, COO(alkyl or aryl) having from 1 to 10 carbon atoms, phenyl, aromatic or heteroaromatic having from 1 to 10 carbon atoms, methyl or alkyl having from 2 to 18 carbon atoms; and

Z is a glycosyl, or substituted aliphatic or aromatic acyl having from 1 to 18 carbon atoms, attached to the carbamoyl O of B at the anomeric carbon of Z.

15. A compound as in claim 14 wherein Z is a galactosyl or glucuronyl or salt or ester having 1 to 4 carbon atoms, thereof.

16. A compound of the formula

5




where:

10 R^1 is a radical of an anthracycline such as doxorubicin, daunorubicin or a derivative thereof where the point of attachment is the 3' nitrogen of the daunosamine sugar;

$n = 2$ or 3 ;

B is COO or one of the following aromatics:

15



20

where B is attached to R^1 via the CH_2 or CH_2OCO of B; and D is attached to Z, and D is O or $NHCOO$ where Z is attached at the carbamoyl O;

M is NO_2 , CN, F, Cl, OH, alkoxy having from 1 to 18 carbon atoms, COMe, CF_3 , COOH, COO(alkyl or aryl) having from 1 to 10 carbon atoms, phenyl, aromatic or heteroaromatic having from 1 to 10 carbon atoms, methyl or alkyl having from 2 to 18 carbon atoms;

Z is a glycosyl, or substituted aliphatic or aromatic acyl having from 1 to 18 carbon atoms, attached to the O of D at the anomeric carbon of Z; and


L is a latent aldehyde or methyl ketone.

10

17. A compound as in claim 16 wherein Z is a galactosyl or glucuronyl or salt or ester having 1 to 4 carbon atoms, thereof.

18. A compound of the formula

15




where:

$Y = F, Cl \text{ or } Br;$

R^1 is a radical of an anthracyclinone such as doxorubicin, daunorubicin or a derivative thereof where the point of attachment is the 3' nitrogen of the daunosamine sugar;

$n = 1$ or 2 ;

5 B is O, NHCOO, or one of the following substituted aromatics:




where M is H, NO₂, CN, F, Cl, OH, alkoxy having from 1 to 18 carbon atoms, COMe, CF₃, COOH, COO(alkyl or aryl) having from 1 to 10 carbon atoms, phenyl, aromatic or heteroaromatic having from 1 to 10 carbon atoms, methyl or alkyl having from 2 to 18 carbon atoms; and

Z is a glycosyl, or substituted aliphatic or aromatic acyl having from 1 to 18 carbon atoms, attached to the aromatic or carbamoyl O of B at the anomeric carbon of Z.

19. A compound as in claim 18 wherein Z is a galactosyl or glucuronyl or salt or ester having 1 to 4 carbon atoms, thereof.

20. A compound of the formula

5



10 where:


Y = F, Cl or Br;

R¹ is a radical of an anthracyclinone such as doxorubicin, daunorubicin or a derivative thereof where the point of attachment is the 3' nitrogen of the daunosamine sugar;

15 n = 1 or 2;

B is O, NHCOO, or one of the following substituted aromatics:

20




where M is H, NO₂, CN, F, Cl, OH, alkoxy having from 1 to 18 carbon atoms, COMe, CF₃, COOH, COO(alkyl or aryl) having from 1 to 10 carbon atoms, phenyl, aromatic or heteroaromatic having from 1 to 10 carbon atoms, methyl or alkyl having from 2 to 18 carbon atoms; and

5. Z is a glycosyl, or substituted aliphatic or aromatic acyl having from 1 to 18 carbon atoms, attached to the aromatic or carbamoyl O of B at the anomeric carbon of Z.

21. A compound as in claim 20 wherein Z is a galactosyl or glucuronyl or salt or ester having 1 to 4 carbon atoms, thereof.

22. A compound of the formula

15



where


Y = F, Cl, Br;

R^1 is a radical of an anthracyclinone such as doxorubicin, daunorubicin or a derivative thereof where the point of attachment is the 3' nitrogen of the daunosamine sugar;

R^2 is H, alkyl having from 1 to 6 carbon atoms, phenyl or aromatic or
 5 heteroaromatic having from 1 to 10 carbon atoms substituted with NO_2 , CN, F, Cl, OH, OMe, or alkoxy having from 1 to 6 carbon atoms, COMe, CF_3 , COOH, COO(alkyl or aryl) having from 1 to 10 carbon atoms;

B is O, NHCOO, or one of the following substituted aromatics:

10




15

where M is H, NO_2 , CN, F, Cl, OH, alkoxy having from 1 to 18 carbon atoms, COMe, CF_3 , COOH, COO(alkyl or aryl) having from 1 to 10 carbon atoms, phenyl, aromatic or heteroaromatic having from 1 to 10 carbon atoms,
 20 methyl or alkyl having from 2 to 18 carbon atoms; and

Z is a glycosyl, or substituted aliphatic or aromatic acyl having from 1 to 18 carbon atoms, attached to the aromatic or carbamoyl O of B at the anomeric carbon of Z.

23 A compound as in claim 20 wherein Z is a galactosyl or glucuronyl or salt or ester having 1 to 4 carbon atoms, thereof.

24. A compound of the formula



where

R^1 is a radical of an anthracycline where the point of attachment is the 3' nitrogen of the daunosamine sugar;

R^2 is H, alkyl having from 1 to 6 carbon atoms, phenyl or aromatic or heteroaromatic having from 1 to 10 carbon atoms substituted with NO_2 , CN, F, Cl, OH, OMe, or alkoxy having from 1 to 6 carbon atoms, COMe, CF_3 , COOH, COO(alkyl or aryl) having from 1 to 10 carbon atoms;


20 $n = 1$ or 2;

M is H, NO₂, CN, F, Cl, OH, alkoxy having from 1 to 18 carbon atoms, COMe, CF₃, COOH, COO(alkyl or aryl) having from 1 to 10 carbon atoms, phenyl, aromatic or heteroaromatic having from 1 to 10 carbon atoms, methyl or alkyl having from 2 to 18 carbon atoms; and

5 Z is a glycosyl.

25. A compound as in claim 24 wherein Z is a galactosyl or glucuronyl or salt or ester having 1 to 4 carbon atoms, thereof.

10 26. A compound of the formula



15

where:

20 R⁴ and R⁵ are the same or different and are alkyl, aryl, or heteroaryl having from 1 to 10 carbon atoms;

R^1 is a radical of an anthracyclinone where the point of attachment is the 3' nitrogen of the daunosamine sugar;

R^2 is H, alkyl having from 1 to 6 carbon atoms, phenyl or aromatic or heteroaromatic having from 1 to 10 carbon atoms substituted with NO_2 , CN, F, Cl, OH, OMe, or alkoxy having from 1 to 6 carbon atoms, COMe, CF_3 , COOH, COO(alkyl or aryl) having from 1 to 10 carbon atoms;


$n = 1$ or 2 ;

M is H, NO_2 , CN, F, Cl, OH, alkoxy having from 1 to 18 carbon atoms, COMe, CF_3 , COOH, COO(alkyl or aryl) having from 1 to 10 carbon atoms, phenyl, aromatic or heteroaromatic having from 1 to 10 carbon atoms, methyl or alkyl having from 2 to 18 carbon atoms; and

Z is a glycosyl.

27. A compound as in claim 26 wherein Z is a galactosyl or glucuronyl or salt or ester having 1 to 4 carbon atoms. thereof.

28. A compound of the formula



10 where:

R^1 is a radical of an anthracycline where the point of attachment is the 3' nitrogen of the daunosamine sugar;

R^2 is H, alkyl having from 1 to 6 carbon atoms, phenyl or aromatic or heteroaromatic having from 1 to 10 carbon atoms substituted with NO_2 , CN, F, Cl, OH, OMe, or alkoxy having from 1 to 6 carbon atoms, COMe, CF_3 , COOH, COO(alkyl or aryl) having from 1 to 10 carbon atoms;

15

R^4 and R^5 are the same or different and are alkyl, aryl, or heteroaryl having from 1 to 10 carbon atoms;

$n = 1$ or 2 ;

20 M is H, NO_2 , CN, F, Cl, OH, alkoxy having from 1 to 18 carbon atoms, COMe, CF_3 , COOH, COO(alkyl or aryl) having from 1 to 10 carbon atoms,


phenyl, aromatic or heteroaromatic having from 1 to 10 carbon atoms, methyl or alkyl having from 2 to 18 carbon atoms; and

Z is a glycosyl.

- 5 29. A compound as in claim 28 wherein Z is a galactosyl or glucuronyl or salt or ester having 1 to 4 carbon atoms, thereof.

30. A compound as in claim 1 having the formula


10



- 15 wherein R¹ is a radical of daunorubicin or doxorubicin where the point of attachment is the 3' nitrogen of the daunosamine sugar.


31. A compound as in claim 1 having the formula

20



wherein R^1 is a radical of daunorubicin or doxorubicin where the point of attachment is the 3' nitrogen of the daunosamine sugar.


5 32. A compound as in claim 1 having the formula



10


wherein R^1 is a radical of daunorubicin or doxorubicin where the point of attachment is the 3' nitrogen of the daunosamine sugar.

33. A compound as in claim 1 having the formula



wherein R^1 is a radical of daunorubicin or doxorubicin where the point of attachment is the 3' nitrogen of the daunosamine sugar.


34. A compound as in claim 10 having the formula



wherein R^1 is a radical of daunorubicin or doxorubicin where the point of attachment is the 3' nitrogen of the daunosamine sugar.

35. A compound as in claim 1 having the formula

65




5

wherein R^1 is a radical of daunorubicin or doxorubicin where the point of attachment is the 3' nitrogen of the daunosamine sugar

10

36. A compound as in claim 1 having the formula




15

wherein R^1 is a radical of daunorubicin or doxorubicin where the point of attachment is the 3' nitrogen of the daunosamine sugar.

20

37. A compound as in claim 12 having the formula




5

wherein R¹ is a radical of daunorubicin or doxorubicin where the point of attachment is the 3' nitrogen of the daunosamine sugar

10

38. A compound as in claim 12 having the formula




15

wherein R¹ is a radical of daunorubicin or doxorubicin where the point of attachment is the 3' nitrogen of the daunosamine sugar.

20

39. A compound as in claim 16 having the formula

67




5

wherein R¹ is a radical of daunorubicin or doxorubicin where the point of attachment is the 3' nitrogen of the daunosamine sugar.

10

40. A compound as in claim 16 having the formula



15


20

wherein R^1 is a radical of daunorubicin or doxorubicin where the point of attachment is the 3' nitrogen of the daunosamine sugar.

41. A compound as in claim 16 having the formula

5

10



15

wherein R^1 is a radical of daunorubicin or doxorubicin where the point of attachment is the 3' nitrogen of the daunosamine sugar.

20

42. A method for the stereoselective synthesis of 1-O-trimethylsilyl-glycosides comprising mixing the corresponding α - and β -glycosyl alcohols

with N-trimethylsilyldialkylamine and nonhydroxylic solvent at room temperature.

43. A method as in claim 42 wherein said N-trimethylsilyldialkylamine
5 is N-trimethylsilyldiethylamine, and said nonhydroxylic solvent is acetone.

44. A method for synthesizing methyl 2,3,4-tri-O-acetyl-1-O-
trimethylsilyl- β -D-glucopyranuronate comprising mixing methyl 2,3,4-tri-O-
acetyl- α/β -D-glucopyranuronate with N-trimethylsilyldialkylamine and
10 nonhydroxylic solvent at room temperature.

45. A method as in claim 44 wherein said N-trimethylsilyldialkylamine
is N-trimethylsilyldiethylamine and said nonhydroxylic solvent is acetone

15 46. A method of inhibiting tumor growth comprising administering a
compound of claim 1.

47. A method of inhibiting tumor growth comprising administering a
compound of claim 30.

48. A method of inhibiting tumor growth comprising administering a compound of claim 31.

49. A method of inhibiting tumor growth comprising administering a
5 compound of claim 32.

50. A method as in claim 46 further comprising administering an enzyme capable of converting said compound to a more active form

10 51. A method as in claim 50 wherein said enzyme is a glycosidase.

52. A method as in claim 51 wherein said enzyme is targeted.

53. A method as in claim 52 wherein the targeted enzyme is an enzyme
15 coupled to an antibody.

54. A method of inhibiting an infectious organism or microbial growth comprising administering a compound of claim 1.


20 55. A method as in claim 54 further comprising administering an enzyme capable of converting said compound to a more active form.

56. A method as in claim 54 wherein said enzyme is targeted.

57. A method as in claim 56 wherein the targeted enzyme is an enzyme coupled to an antibody.







1/7

Fig. 1




2/7

Fig.2




3/7

*Fig.3*

4/7

Fig. 4



5/7




Fig.5






Fig. 6

7/7

Fig. 7




Scheme 1.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/05920

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) : C07H 15/24 US CL : 536/6.4 According to International Patent Classification (IPC) or to both national classification and IPC																								
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 536/6.4 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAPLUS - structure search																								
C. DOCUMENTS CONSIDERED TO BE RELEVANT																								
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																						
A	LEENDERS et al. β -Glucuronyl Carbamate Based Pro-moieties Designed for Prodrugs in ADEPT. Tetrahedron Letters. 1995, Vol. 36, No. 10, pages 1701-1704.	1-41																						
A	CHERIF et al. <i>N</i> -(5,5-Diacetoxypent-1-yl)doxorubicin: A New Intensely Potent Doxorubicin Analogue. J. Med. Chem. 1992, Vol. 35, No. 17, pages 3208-3214, especially page 3208.	1-41																						
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																								
<table border="0"><tr><td>* Special categories of cited documents:</td><td>* T</td><td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td></tr><tr><td>* A</td><td>document defining the general state of the art which is not considered to be of particular relevance</td><td></td></tr><tr><td>* E</td><td>earlier document published on or after the international filing date</td><td>* X</td><td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td></tr><tr><td>* L</td><td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td><td>* Y</td><td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td></tr><tr><td>* O</td><td>document referring to an oral disclosure, use, exhibition or other means</td><td>* A</td><td>document member of the same patent family</td></tr><tr><td>* P</td><td>document published prior to the international filing date but later than the priority date claimed</td><td></td><td></td></tr></table>			* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	* A	document defining the general state of the art which is not considered to be of particular relevance		* E	earlier document published on or after the international filing date	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	* L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	* O	document referring to an oral disclosure, use, exhibition or other means	* A	document member of the same patent family	* P	document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																						
* A	document defining the general state of the art which is not considered to be of particular relevance																							
* E	earlier document published on or after the international filing date	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																					
* L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																					
* O	document referring to an oral disclosure, use, exhibition or other means	* A	document member of the same patent family																					
* P	document published prior to the international filing date but later than the priority date claimed																							
Date of the actual completion of the international search 01 AUGUST 1997		Date of mailing of the international search report 29 AUG 1997																						
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer EVERETT WHITE  Telephone No. (703) 308-1235																						

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/05920

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-41

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/05920

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-41, drawn to compound in which daunorubicin or doxorubicin is part of the compound, classified in class 549, subclass 424.

Group II, claims 42-45, drawn to method of use in which 1-O-trimethylsilylglycosides are synthesized classified in class 514, subclass 63.

Group III, claims 46-49 and 54, drawn to method of use in which tumor growth is inhibited by compounds of the claims classified in class 549, subclass 214.

Group IV, claims 50-53 and 55-57, drawn to method of use, in which an enzyme is part of the method of use classified in class 514, subclass 12.

and it considers that the International Application does not comply with the requirements of unity of invention (Rules 13.1, 13.2 and 13.3) for the reasons indicated below:

The inventions listed as Groups I-IV do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the compounds of Group I do not correspond to the method of use of Group II, they are drawn to dissimilar inventions. They are made and used independently. The method of use of Group III, drawn to compounds in which tumor growth is inhibited, also represents an independent group, it shares no features with Group II or Group I. Group IV, drawn to method of use in which an enzyme is part of the method of use, is an independent group sharing no features with Groups I-III.